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RNA NANOPARTICLES AND METHOD OF
USE THEREOF

In some embodiments, the presently disclosed subject
matter relates to an artificial RNA nanostructure molecule.
The molecule includes a RNA junction motif comprising a
plurality of branches and at least one imaging module,
wherein a branch of the RNA junction motif comprises at
least one RNA oligonucleotide. Non-limiting examples of
the imaging module includes fluorescence dyes, radionuclides, and/or contrast agents. Non-limiting examples of
fluorescent dye include Alexa dyes, Cy dyes or Near Infrared
dyes. Further non-limiting examples of fluorescent dye
include Alexa dye, Cy dyes, Near Infrared (Near IR or NIR)
dyes, including but not limited to, IRdye 800 , Alexa 647 , Cy5,
Cy5.5, Alexa680, Iowa Black RQ, QSY21, IRDyeQC,
BBQ650, BHQ-3, Indocyanine green (ICG). In some
embodiments, the imaging module comprises a reporter
imaging module. In some embodiments, the imaging module comprises a reference imaging module. In some embodiments, the reference imaging module comprises a reference
dye and a quencher. In some embodiments, the RNA molecule further includes at least one cancer targeting module
coupled to the RNA junction motif. In some embodiments,
the molecule further includes at least one therapeutic module
coupled to the RNA junction motif. In some embodiments,
the imaging module is coupled to at least one branch of the
RNA junction motif. In some embodiments, the imaging
module is coupled to any branch of the RNA junction motif.
In some embodiments, the imaging module is coupled to the
cancer targeting module. In some embodiments, the imaging
module is coupled to the therapeutic module. In some
embodiments, the plurality of branches comprises three
branches, four branches, five branches, six branches, seven
branches eight or more branches. In one embodiment, the
plurality of branches comprising the RNA junction motif
includes a three-branched RNA junction motif. In one
embodiment, the plurality of branches comprising the RNA
junction motif comprises a four-branched RNA junction
motif.
In some embodiment of the presently disclosed subject
matter, the RNA nanostructure includes a radionuclide. In
some embodiments, the term "radionuclide" includes radiolabel peptides and proteins with various isotopes. Nonlimiting examples of the radioisotopes includes 177Lu, 111 In,
64Cu, 99mTc, 230Pb, issRe, 212Pb/212Bi. In some embodiments, the radionuclide is coupled to more than one branch
of the RNA junction motif. In some embodiment, the
radionuclide is chelated by a chelating agent. In some
embodiments, the chelating agent is conjugated to at least
one branch of the RNA junction motif. Nonlimiting
examples of the chelating agent is EDTA, DOTA, NOTA.
[0058] In some embodiments, the RNA molecule includes a
contrast agent. In some embodiments, the contract agent is
a MRI contrast agent. In some embodiments, the MRI
contract agent is gastrointestinal MRI, intravenous MRI,
intravascular (blood pool) MRI tumor-specific MRI, hepatobiliary MRI and reticuloendothelial MRI. One non-limiting example of the MRI contrast agent is a gadolinium
contrast agent.
In some embodiments, the nanostructure comprises at
least one chemical modification at a 2' position of the RNA
oligonucleotide. In some embodiments, the chemical modification comprises 2'Fluoro, 2'Amine, and 2'O-Methyl.
In some embodiments of the presently disclosed subject
matter, a branch of the three-branched RNA junction motif
is an a3WJ RNA module (SEQ ID NO: 1), a b3WJ RNA
module (SEQ ID NO: 2), or a c3WJ RNA module (SEQ ID
NO: 3). In one embodiment, the three-branched RNA junction motif comprises an a3WJ RNA module (SEQ ID NO:
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TECHNICAL FIELD
The presently-disclosed subject matter relates to an artificial RNA nanostructure and method of use thereof. In
particular, the presently-disclosed subject matter relates to
RNA nanoparticles and RNA dendrimers, and methods of
disease diagnosis and treatments using RNA nanostructure
and RNA dendrimers.
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INTRODUCTION
Cancer is a broad class of diseases featuring uncontrollable cell growth, invasion, and destruction of nearby tissues
and metastasis [1, 2]. Cancer has become one of the leading
causes of death in the world, accounting for about 7.6
million deaths in 2008 [3]. The economic burden of cancer
is also very high, to both the person with cancer and for the
whole society. According to the estimation by the National
Institutes of Health (NIH), the overall annual cost of cancer
in 2008 was $201.5 billion [4]. Thus, an effective, efficient,
and safe treatment for cancer is urgently needed.
SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. This Summary does not list or suggest all possible combinations of
such features.
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1), a b3 WJ RNA module (SEQ ID NO: 2), and a c3 WJ RNA
module (SEQ ID NO: 3). In some embodiments, SEQ ID
NO: 1 has at least 90% identity to nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3'. In one embodiment, SEQ ID NO: 1 comprises nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3'. In some embodiments, SEQ ID NO: 2 has at least 90% identity to nucleotide
sequence 5'-CCCACA UAC UUU GUU GAUCC-3'. In one
embodiment, SEQ ID NO: 2 comprises nucleotide sequence
5'-CCC ACA UAC UUU GUU GAUCC-3'. In some
embodiments, SEQ ID NO: 3 has at least 90% identity to
nucleotide sequence 5'-GGA UCAAUC AUG GCAA-3'. In
one embodiment, SEQ ID NO: 3 comprises nucleotide
sequence 5'-GGA UCAAUC AUG GCAA-3'.
In some embodiments of the presently disclosed subject
matter, the RNA nanostructure includes a cancer targeting
module. In some embodiments, the presently disclosed
subject matter provides that the targeting module in the
artificial RNA nano structure molecule includes a ligand that
binds to at least one cancer cell surface marker. In some
embodiments, the cancer targeting module is a colon cancer
targeting module. Non-limiting examples of folate include
5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, folic acid and other folate compounds. In some embodiments, the therapeutic module comprises a siRNA, a miRNA, an anti-mRNA, a ribozyme RNA,
or an antisense RNA. In some embodiments, In some
embodiments, the therapeutic module comprises a chemotherapeutic drug, a riboswitch, or an endosome disrupting
agent. In some embodiments, the therapeutic module is a
siRNA sequence. In one embodiment, the siRNA directly
binds to survivin. In some embodiments, the siRNA directly
binds to PI3K, Akt, or mTOR. In some embodiments, the
therapeutic module is a microRNA sequence. In some
embodiments, the therapeutic module is an anti-miRNA
molecule directed to a miRNA comprising miR-9, miR-1 Ob,
miR-21, or miR-26. In some embodiments, the therapeutical
module is a miRNA molecule for a miRNA comprising
let-7a, miR-l0b, miR-25, miR-34a, miR-124, miR-145, or
miR-181b. In some embodiments, the therapeutic module is
a cytotoxic drug. In some embodiments, the cytotoxic drug
comprises doxorubicin, paclitaxel, paclitaxel derivatives and
analogues, cytochalasin D, rapamycin, rapamycin derivatives and analogues, camptothecin, dexamethasone, and
5-fluorouracil, a quinazolinone derivative, metallic silver,
tranilast, everolimus and/or related compounds.
In another aspect, the presently disclosed subject matter
provides an artificial RNA nanostructure molecule includes
a RNA junction motif comprising a plurality of branches and
a radiation-based therapeutic module coupled to the RNA
junction motif, and a branch of the RNA junction motif
includes at least one RNA oligonucleotide. In some embodiments, the molecule further includes a cancer targeting
module coupled to the RNA junction motif. In some embodiments, the molecule further includes an imaging module
coupled to the RNA junction motif. In some embodiments,
the nanostructure comprises at least one chemical modification at 2' position of the RNA oligonucleotide. In some
embodiments, the chemical modification comprises
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments,
the plurality of branches comprises three branches, four
branches, five branches, six branches, seven branches, eight
or more branches. In some embodiments, the plurality of
branches comprising the RNA junction motif includes a
three-branched RNA junction motif. In some embodiments,
the plurality of branches comprising the RNA junction motif
comprises a four-branched RNA junction motif. In some

embodiments, a branch of the three-branched RNA junction
motif includes an a3WJ RNA module (SEQ ID NO: 1), a
b3WJ RNA module (SEQ ID NO: 2), or a c3WJ RNA
module (SEQ ID NO: 3). In some embodiments, the threebranched RNA junction motif comprises an a3WJ RNA
module (SEQ ID NO: 1), a b3WJ RNA module (SEQ ID
NO: 2), and a c3WJ RNA module (SEQ ID NO: 3). In some
embodiments, SEQ ID NO: 1 has at least 90% identity to
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG3'. In some embodiments, SEQ ID NO: 1 comprises nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-3'. In
some embodiments, SEQ ID NO: 2 has at least 90% identity
to nucleotide sequence 5'-CCC ACA UAC UUU GUU
GAUCC-3'. In some embodiments, SEQ ID NO: 2 comprises nucleotide sequence 5'-CCC ACA UAC UUU GUU
GAUCC-3'. In some embodiments, SEQ ID NO: 3 has at
least 90% identity to nucleotide sequence 5'-GGA UCA
AUCAUG GCAA-3'. In some embodiments, SEQ ID NO:
3 comprises nucleotide sequence 5'-GGA UCA AUC AUG
GCAA-3'. In some embodiments, the cancer-targeting module is a cancer cell-specific ligand. In some embodiments,
the cancer-targeting module is folate. In some embodiments,
cancer-targeting module is an RNA aptamer. In some
embodiments, the radiation-based therapeutic module
include a isotope. Nonlimiting examples of the isotope
include 177Lu, lllln, 64Cu, 99mTc, 203Pb, 188Re, 212Pb,
212Bi, I-125, or Cs-131.
Further, in another aspect of the present subject matter, a
RNA dendrimer molecule is provided. The molecule
includes (a) a central core multi-branched RNA junction
motif, wherein the central core motif comprises a plurality
of branches, and wherein a branch comprises at least one
RNA oligonucleotide; and (b) an outer surface multibranched RNA junction motif comprising at least one
repeating multi-branched RNA junction motif unit, wherein
the repeating unit comprises a plurality of branches, and
wherein a branch comprises at least one RNA oligonucleotide. In some embodiments, the dendrimer further includes
at least one imaging module. In some embodiments, the
dendrimer includes at least one targeting module. In some
embodiments, the dendrimer further includes at least one
therapeutic module. In some embodiments, the plurality of
branches includes the central core multi-branched RNA
junction motif comprises a three-branched RNA junction
motif, a four-branched RNA junction motif, five-branched
RNA junction motif, a six-branched RNA junction motif,
seven-branched RNA junction motif, an eight or more
branched RNA junction motif. In some embodiments, the
plurality of branches comprising the repeating multibranched RNA junction motif unit includes a three-branched
RNA junction motif, a four-branched RNA junction motif,
five-branched RNA junction motif, a six-branched RNA
junction motif, seven-branched RNA junction motif, an
eight or more branched RNA junction motif. In some
embodiments, a branch of the three-branched RNA junction
motif comprises an a3WJ RNA module (SEQ ID NO: 1); a
b3WJ RNA module (SEQ ID NO: 2); or a c3WJ RNA
module (SEQ ID NO: 3). In one embodiments, the threebranched RNA junction motif comprises an a3WJ RNA
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID
NO: 2); and a c3WJ RNA module (SEQ ID NO: 3). In some
embodiments, SEQ ID NO: 1 has at least 90% identity to
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG3'. In some embodiments, SEQ ID NO: 2 has at least 90%
identity to nucleotide sequence 5'-CCC ACA UAC UUU
GUU GAUCC-3'. In some embodiments, SEQ ID NO: 3 has
at least 90% identity to nucleotide sequence 5'-GGA UCA
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AUC AUG GCA A-3'. In some embodiments, the central
core multi-branched RNA junction motif is a polygon
shaped architecture comprising a three-branched RNA junction motif at each comer. In some embodiments, the imaging
module comprises a fluorescent dye, a radionuclide, or a
contrast agent. In some embodiments, fluorescent dye is a
Alexa dye, Cy dyes or Near IR dyes. Nonlimiting of
fluorescent dye include IRdye800, Alexa647, Cy5, Cy5.5,
Alexa680, Iowa Black RQ, QSY21, IRDyeQC, BBQ650,
BHQ-3, Indocyanine green (ICG). In some embodiments,
the imaging module comprises a reporter imaging module.
In some embodiments, the imaging module comprises a
reference imaging module. In some embodiments, the reference imaging module comprises a reference dye and a
quencher. In some embodiments, the imaging module comprises at least one fluorescent dye. In some embodiments,
the imaging module include a radionuclide and/or a contrast
agent. A nonlimiting example of contrast agent is a MRI
contrast agent. In one embodiment, the imaging module
includes at least one gadolinium contrast agent. In some
embodiments, the targeting module includes a cancer targeting module. In some embodiments, the cancer targeting
module is a ligand that binds to at least one cancer cell
surface marker. In some embodiments, the RNA dendrimer
contains a targeting module comprises a chemical ligand
and/or a RNA aptamer. A nonlimiting example of the ligand
includes folate. In some embodiments, the cell surface
markers comprises a folate receptor. In some embodiments,
the ligand binds to an epithelial cell adhesion molecule
(EpCAM). In some embodiments, the cell surface marker
comprises an epithelial cell adhesion molecule (EpCAM). In
some embodiments, the cancer targeting module comprises
an aptamer. A non-limiting example of the aptamer is an
EpCAM RNA aptamer. In some embodiments, the cancer
targeting module is a folate. Nonlimiting examples of the
folate include folic acid, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or a
combination thereof. In some embodiments, the therapeutic
module comprises a siRNA, a miRNA, an anti-mRNA, a
ribozyme RNA, or an antisense RNA. In some embodiments, the therapeutic module comprises a chemotherapeutic drug, a riboswitch, or an endosome disrupting agent. In
some embodiments, the therapeutic module is a cytotoxic
drug. Nonlimiting examples of the cytotoxic drug include
doxorubicin, paclitaxel, paclitaxel derivatives and analogues, cytochalasin D, rapamycin, rapamycin derivatives
and analogues, camptothecin, dexamethasone, and 5-fluorouracil, a quinazolinone derivative, metallic silver, tranilast, everolimus and related compounds, or other agents that
inhibit cell proliferation and or migration and/or inflammatory processes. In some embodiments, the plurality of
branches of the multi-branched comprises at least 90%
identity to nucleotide sequences of at least one of SEQ ID
NOS: 1-20.
In another aspect of the presently disclosed subject matter,
is a composition comprising a therapeutically effective
amount of the RNA nanostructure molecule and RNA dendrimer as disclosed above and herein. In some embodiments,
the composition further includes a pharmaceutically acceptable carrier.
Yet in another aspect of the presently disclosed subject
matter, is a drug delivery system, the system comprising a
therapeutically effective amount of the RNA nanostructure
and the RNA dendrimer molecule as disclosed above and
herein. In some embodiments, drug delivery system further
includes a pharmaceutically acceptable carrier.

Further, in some embodiments, the presently disclosed
subject matter provide a method of image-guided drug
delivery of a therapeutic agent to a subject in need thereof.
The method include administering a therapeutically effective amount of RNA nanostructure molecule and RNA
dendrimer as disclosed above and herein, and applying an
imaging detection apparatus to the subject. In some embodiments, the imaging detection apparatus is an MRI imaging
system. In some embodiments, the imaging detection apparatus is an NIRF imaging system. In some embodiments, the
imaging detection apparatus is an CT/PET/SPECT imaging
system.
In some embodiments of the present subject matter, is a
method of diagnosing and/or treating a disease in a subject
having or at risk of having the disease. The method comprising administering to the subject a therapeutically effective amount of a composition comprising a RNA nano structure and/or RNA dendrimer as disclosed herein. In some
embodiments, the composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the
subject is a mammal or a non-mammal vertebrate. In some
embodiments, the subject is a human. In some embodiments,
the disease includes but not limited to ovarian cancer, brain
cancer, bone cancer, lung cancer, colorectal cancer.

5

10

15

20

25

BRIEF DESCRIPTION OF THE DRAWINGS

30

35

40

45

50

55

60

65

FIG. 1 shows structure, assembly and characterization of
RNA 3WJ nanoparticles. A. Secondary structure of the
pRNA 3WJ (FIG. lA discloses SEQ ID NOS 1, 3 and 2,
respectively, in order of appearance). B. Eight representative
images of RNA 3WJ-pRNA nanoparticles are shown in
magnified view and the images reveal a three-branch shape
of the RNA nanoparticles. The AFM images of the RNA
nanoparticles were obtained on APS-modified mica surface
by a Veeco MultiMode AFM NanoScope IV system. (Scale
bar: 10 nm). C. 12% native PAGE demonstrates the stepwise assembly of RNA 3WJ nanoparticles, stained by
ethidium bromide (upper) and SYBR Green II (lower).
Lane: 1: 3WJa (SEQ ID NO: 1); 2: 3WJ6 (SEQ ID NO: 2);
3: 3WJc (SEQ ID NO: 3); 4: 3WJa+3WJb (SEQ ID NO: 1,
SEQ ID NO: 2); 5: 3WJa+3WJc (SEQ ID NO: 1, SEQ ID
NO: 3); 6: 3WJb+3WJC (SEQ ID NO: 2, SEQ ID NO: 3); 7:
3WJa+3WJb+3WJc (SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID
NO: 3). D. The thermodynamic stability of assembled RNA
3WJ nanoparticles was revealed by using the TGGE system.
The temperature gradient was set from 36 to 80° C., and the
direction was set as perpendicular to the electric field. The
left two lanes are the 3WJ fragments and the 3WJ complex
starts at the third lane.
FIG. 2 shows targeting, uptake, and cytotoxicity of RNA
3WJ nanoparticles. A. Confocal images showing the uptake
comparison of the folate-3WJ RNA nanoparticles and 3WJ
only RNA nanoparticles to colon cancer HT29 cells by
colocalization of nucleus (blue), actin (green) andAlexa647labeled RNAnanoparticles (red) signals. B. Flow cytometry
analysis showing the binding of folate labeled 3 WJ 2'F RNA
nanoparticles to folate receptor over-expressed KB cells.
Black curve: cell only control; blue curve: 3WJ RNA
nanoparticles without folate; red curve: 3WJ RNAnanoparticles with folate. C. Effect of the folate-3WJ RNA nanoparticles on HT29 cells viability. The cells were incubate
with three different concentration (100 nM, 200 nM and 400
nM) of the folate-3WJ RNA nanoparticles. D. The folate3WJ-Alexa647 were injected intravenously into nude mice
with HT29 subcutaneous xenografts. Accumulation of fluo-
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rescently labeled folate-3WJ nanoparticles in tumor, liver
and lung was evaluated by IVIS Spectrum station.
FIG. 3 show stability assay ofRNA3WJ nanoparticles for
urea, serum and irradiation. A. 12% native PAGE demonstrates the stability ofRNA3WJ nanoparticles against 2 M-8
M Urea denaturation. The gel was stained by ethidium
bromide. Lane: 1: 3WJa (SEQ ID NO: 1); 2: 3WJ6 (SEQ ID
NO: 2); 3: 3WJc (SEQ ID NO: 3); 4: 3WJa+3WJb (SEQ ID
NO: 1, SEQ ID NO: 2); 5: 3WJa+3WJc (SEQ ID NO: 1, SEQ
ID NO: 3); 6: 3WJb+3WJC (SEQ ID NO: 2, SEQ ID NO: 3);
7: 3WJa+3WJb+3WJc (SEQ ID NO: 1, SEQ ID NO: 2, SEQ
ID NO: 3). B. Nanoparticle stability in serum was compared
between 2'F modified and non-modified RNA 3WJ nanoparticles for up to 36 hr. Black square: RNA nanoparticle;
red sphere: 2'F RNA nanoparticle. C. RNA 3WJ nanoparticles were resistant to radiation. 2'F-modified RNA 3WJ
nanoparticles were examined by 12% native PAGE with
TBM running buffer after 7-day irradiation with Cs-131 or
18-day irradiation with I-125. A dose of30 Gy was given by
both Cs-131 and I-125. No obvious change was detected
after 7-day or 18-day irradiation. Lane: 1: RNA nanoparticles without irradiation; 2: RNA nanoparticles after 7-day
irradiation (30 Gy) with Cs-131; 3: RNAnanoparticles after
18-day irradiation (30 Gy) with I-125. D. Plasmid DNA was
damaged by radiation. Plasmid DNA was examined by 0.7%
agarose gel with TAE running buffer after 7-day irradiation
(30 Gy) with Cs-131 or 18-day irradiation (30 Gy) with
I-125. Plasmid DNA was damaged after both 7-day and
18-day irradiation. Lane: 1 & 3: Plasmid DNA without
irradiation; 2: Plasmid DNA after 7-day irradiation (30 Gy)
with Cs-131; 4: Plasmid DNA after 18-day irradiation (30
Gy) with I-125.
FIG. 4 includes diagrams illustrating comparison of (A)
conventional molecular beacon and (B) RNA nanotechnology-based 3WJ-Beacons. FIG. 4B discloses SEQ ID NOS 1,
3 and 2, respectively, in order of appearance.
FIG. 5 includes construction of pRNA-3WJ based RNA
Dendrimers (G0-G3) for harboring multiple gadolinium
contrast agents for MRI Imaging and radionuclides for
PET/SPECT imaging.
FIG. 6 includes (A) phi29 DNA packaging motor. (B)
pRNA hexamer derived from the crystal in (D)14. (C)
Hexameric pRNA nanoparticles. (D) pRNA-3WJ crystals
and X-ray diffraction pattern14. (E) pRNA monomer (SEQ
ID NO: 33). Box: 3WJ domain. (F) 3WJ domain9 composed
of three fragments a3wJ, b3wJ, and c3wJ. Hl-3: helical
segments (FIG. 6F discloses SEQ ID NOS 1, 3 and 2,
respectively, in order of appearance).
FIG. 7 includes competition and dissociation assays of
pRNA-3WJ nano-particles [G9] (A) Temperature effects:
Fixed concentration of Cy3-pRNA-3WJ core [ab*c h wJ was
incubated with varying concentrations of unlabeled b 3 wJ at
37° C. (B) Urea denaturing effects: A fixed concentration of
Cy3-[ ab*c h wJ was incubated with unlabeled b 3 wJ at a 1: 1
ratio in the presence of 0-6 M urea at 25° C. (C) Serial
dilution assay: The [32 P]pRNA-3WJ complex remains intact
even at 160 pM. (D) After 2'-F modification, RNA nanoparticles are chemically stable [G13].
FIG. 8 shows that, compared to 11 different RNA 3WJ
core motifs, the 3 WJ-pRNA motif displayed the highest Tm
with the steepest slope [G9].
FIG. 9 shows RNA nanotechnology approach for constructing polyvalent RNA nanoparticles with various shapes
and sizes [G9-Gll].
FIG. 10 includes (A-B) Ocular delivery of pRNA nanoparticles to cornea and retina following subconjunctival

injection [G18]: (A) whole body (B) confocal images of the
retina showing RNA accumulation after 4 hrs.
FIG. 11 includes (A-B) Upon systemic injection, pRNA3WJ nanoparticles were located specifically at the cancer
xenografts expressing the cancer receptors and were not
detected in any vital organs in the body [G9-ll].
FIG. 12 includes conjugation of 'reference' dye IRdye 800 ,
quencher Iowa Black, and 'reporter' dye Alexa 647 to pRNA3WJ scaffold for fluorescence imaging. Alternatively, radionuclides will be incorporated as 'reference' module for
simultaneous PET/SPECT and fluorescence imaging. Figure
discloses SEQ ID NOS 1, 3 and 2, respectively, in order of
appearance.
FIG. 13 shows emission spectra of the 'reporter' dye
Alexa 647 , and 'reference' dye IRdye 800 , showing no spectral
overlaps.
FIG. 14 shows step-wise preparative scheme for labeling
DOTA conjugated RNA nanoparticles with a radionuclide
(1 77 Lu or 111 In) or contrast agent Gd3 +. For 64Cu, NOTASCN will be used instead. The radiolabeled strand will then
be mixed with the other 3WJ component strands to assemble
the 3WJ nanoparticles. Figure discloses SEQ ID NOS 34,
34, 34, 1, 34 and 2, respectively, in order of appearance.
FIG. 15 shows confocal images showing strong binding
and entry ofpRNA-3WJ-FAnanoparticles into HT29 colon
cancer cells. Magnification: 180x.
FIG. 16 shows confocal images showing strong binding
and entry of Cy5 labeled pRNA-3WJ-EpCAM aptamer
constructs into HT29 colon cancer cells. The aptamer was
selected from our novel 2'-F 3WJ library based on RNA
nanotechnology.
FIG. 17 shows enhanced gene silencing effects of tetravalent pRNA-X nanoparticles harboring different siRNAs targeting different loci on the same gene 10 . RLU: Relative
Luciferase Units.
FIG. 18 (A) shows construction of miR-21-luciferase
reporter system. (B) Schematic of pRNA-3WJ-FA-antimiR21 nanoparticles (FIG. 18A discloses SEQ ID NO: 35).
(C) Upon incubation, specific knock-down miR-21 in KB
cells was observed, compared to controls (without FA or
anti-miR21).
FIG. 19 shows conjugation of Paclitaxel to pRNA-3WJ
using 'click chemistry' approach and acid-labile bonds.
Figure discloses SEQ ID NOS 1, 3 and 2 respectively, in
order of appearance.
FIG. 20 shows preliminary data of Caspase 3 assay
demonstrating cell apoptosis induced by the CPT-RNA
strand. Inset: Design of pRNA-3WJ constructs carrying
Camptothecin (CPT).
FIG. 21 shows working principle ofpRNA-3WJ-Beacon.
Once internalized into the cells and released from the
endosome, the RNA-3WJ-Beacon is processed by RISC and
the siRNA component will be released from the 3WJ complex and away from the quencher, thereby restoring the
fluorescence of 'reporter' dye Alexa647 for real-time imaging
FIG. 22 shows (A) Whole body and (B) Internal organ
images showing that upon systemic injection, pRNA-3WJFAnanoparticles specifically targeted Folate receptor+HT29
colon cancer subcutaneous xenografts and were not detected
in any vital organs in the body, after 8 hrs. (C) Confocal
imaging of fixed frozen tumor xenografts sections confirmed
binding and accumulation of pRNA nanoparticles in vivo.
Control: PBS.
FIG. 23 shows Micro-SPECT/CT imaging ofMDA-MB435 breast cancer subcutaneous xenograft bearing mice 119 .
(A) The whole body SPECT images were fused with con-
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ventional micro-CT images to validate regions of increased
uptake of radiolabeled 111 In-DOTA(GSG)-KCCYSL peptide (SEQ ID NO: 31). (B) The trans-axial SPECT/CT image
focusing on tumor uptake in the xenograft. (Kumar S R, et
al., Clin. Cancer Res. 2007 Oct. 15; 13(20):6070-9).
FIG. 24 shows targeting of metastatic liver cancer by
pRNA-3WJ-Folate nanoparticles. (A) Bio-luminescence
images confirming liver metastasis. The pRNA-3WJ-FAAlexa647 nanoparticles specifically targeted HT29 liver
metastatic cells, but not the normal liver parenchyma cells
after systemic injection, as shown by macroscopic (B) and
histological (C) assays. Control: PBS treated mice. Green:
cancer cells; blue: DAPI for nucleus; magenta: Alexa 647
RNA; White arrows: Folate-pRNA-Alexa647 accumulation
and binding; Yellow arrows: normal liver parenchyma.
FIG. 25 shows pRNA nanoparticles did not induce interferon response 12 , as assayed by (A) IFN of KB cells; (B)
TLR-3,7 and 9 gene for human blood mononuclear cells; (C)
TLR-3 pathway of HEK-Blue-hTLR3 reporter cells.
FIG. 26 shows (A-B) Schematic and AFM images of
RNA dendrimers composed mainly of RNA by branch
extension 11 . (C) 2D structure of Generation-3 RNA Dendrimers using pRNA-3WJ as scaffold for harboring DOTAchelated Gd3 +, radionuclides and/or folate.
FIG. 27 shows In vivo assessment ofliver metastases. (A)
HT29-Luc cells were injected into the spleen to induce liver
metastases. Representative bioluminescence images of mice
with Luc-expressing liver metastases (B) T2 weighted
images acquired on the University of Kentucky small animal
Clinscan MRI scanner depicting multiple liver metastases
(arrows).
FIG. 28 shows (A-B) 2D sequence; assembly in 15%
native PAGE and stability in 8 M urea 15% PAGE; and
thermodynamic properties of pRNA-3WJ (A) and pRNA3WJ-rev (B) scaffold. (FIG. 28A-B discloses SEQ ID NOS
36, 3, 2, 37, 5 and 6, respectively, in order of appearance).
FIG. 29 shows step-wise assembly of three modules used
as building blocks for RNA dendrimer construction. Module-I assembles for three strands: 3WJ-a, 3WJ-b, and 3WJc. Module-2 assembles from three units: pRNA-3WJ harboring a_rev, pRNA-3WJ harboring b_rev, and pRNA-3WJ
harboring c_rev sticky-ends. Module-3 assembles from
three units: pRNA-3WJ harboring a_rev, pRNA-3WJ harboring b_rev, and pRNA-3WJ harboring three c_rev sticky
ends. Right panel: AFM images of the modular building
blocks. For module-I, theAFM image is for 3WJ with three
pRNA subunits at the three branches.
FIG. 30 shows construction of multifunctional RNA
dendrimers. Functionalization of module-3 with varieties of
moieties for targeting (chemical ligand or RNA aptamer),
imaging (fluorophore or radiolabel), and therapeutic
(siRNA, miRNA, anti-miRNA, chemotherapeutic drugs,
ribozyme, riboswitch, endosome disrupting agents) units.
FIG. 31 shows assembly of G-1 to G-4 RNA dendrimers
from component strands. G-0 assembles for three strands:
3WJ-a, 3WJ-b, and 3WJ-c, as shown in FIG. 2A module 1.
(A) G-1 assembles from five strands: A, B, C, D and E with
complementary linkers (black) and 3WJ strands (red). (B)
G-2 assembles from G-1 harboring four 3WJ-b sticky ends,
and 3WJ-a and 3WJ-c strands. (C) G-3 assembles from G-2
harboring eight 3WJ-b_rev sticky ends, and 3WJ-a_rev and
3WJ-c_rev strands. (D) G-4 assembles from G-2 harboring
eight 3WJ-b_rev sticky ends, and a dimer module harboring
3WJ-a_rev and 3WJ-c_rev strands. Please refer to Table 4
for defining characteristics.
FIG. 32 shows (A) 2D structure (left), AFM images
(middle), and 3D model (right) (using Pymol and Swiss

PDB viewer) of G-0 to G-4 RNA dendrimers. (B) 2%
agarose gel showing assembly of G-0 to G-4 RNA dendrimers. (C) Serum stability assay of G-4 RNA dendrimers
assayed in 2% agarose gel and quantified by ImageJ.
FIG. 33 shows (A) Flow cytometry data of G-4 RNA
dendrimers at different concentrations (1 nM, 3 nM and 6
nM) with KB cells. Cell only (black), G-4 dendrimer with no
folate (red); and G-4 with 16 folates (blue). Right: Summary
of binding results. (B) Confocal microscope images of G-4
RNA dendrimers incubated with KB cells, nuclear staining
by DAPI (blue), cell membrane staining by phalloidin
Alexa488 (green), Cy5-labeled folate-G4 dendrimer (red)
and a overlay of three panels. Bottom: Magnified view of
overlayed image section boxed in red.
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The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom.
In certain instances, nucleotides and polypeptides disclosed herein are included in publicly-available databases,
such as GENBANK® and SWISSPROT. Information
including sequences and other information related to such
nucleotides and polypeptides included in such publiclyavailable databases are expressly incorporated by reference.
Unless otherwise indicated or apparent the references to
such publicly-available databases are references to the most
recent version of the database as of the filing date of this
Application.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth to facilitate explanation of the presently-disclosed
subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass varia-
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tions of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
As used herein, the abbreviations for any protective
groups, amino acids and other compounds, are, unless
indicated otherwise, in accord with their common usage,
recognized abbreviations, or the IUPAC-IUB Commission
on Biochemical Nomenclature (see, Biochem. (1972) 11(9):
1726-1732).
The presently-disclosed subject matter includes an artificial RNA nanostructures and RNA dendrimers and methods
of use thereof.
RNA nanotechnology is an unique field [G8,G24], distinct from the classical studies of RNA structure and folding
[G25-31]. In 1998, the feasibility of constructing RNA
nanoparticles by bottom-up self-assembly was first demonstrated. RNA dimer, trimer, and hexamer nanoparticles were
assembled using re-engineered RNA fragments from the
pRNA, a viral component gearing the phi29 DNA packaging
motor (FIG. 6A-C [G32]). This finding (published in
Molecular Cell, and featured in Cell (G32-33)) was the
proof-of-concept for RNA nanotechnology. Generally
speaking, RNA is unique in several aspects: (1) RNA
contains varieties of motifs such as helices, loops, stems,
hairpins, and pseudo-knots to specify rich 3D architectures;
(2) RNA possesses both canonical, noncanonical base pairings(G34-38), as well as base stacking capabilities for interor intra-molecular interactions(G39-40); (3) RNA is thermodynamically more stable than DNA [G9,G10,G39,G40];
(4) RNA displays unique features in transcription, termination, splicing, and self-processing producing RNA fragments that are able to self-assemble into nanoparticles in
vitro and in vivo [G32,G41-45]; and (5) RNA exhibits
functional entities, such as siRNA [G46,G47], ribozyme
[G48,G49], riboswitch [GS0-51], and miRNA [G52-53]. As
disclosed herein, RNA nanotechnology is an important field
due to finding of its high thermodynamic stability, favorable
and distinctive in vivo attributes (US 2014/0179758, hereby
incorporate by reference in its entirety). In some embodiments of the present disclosure, as disclosed in US2014/
0179758, the RNA molecules form dimers, trimers, hexamers, and patterned superstructures.
In nature, several RNA molecules form unique multimers
with diverse functions. In one embodiment, bacteriophage
phi29 pRNA forms dimers and hexamers, via hand-in-hand
interactions, between right- and left-interlocking loops
[G20,G32,G54,G55] (FIG. 6A-C). Unusual properties of an
ultra-stable pRNA 3-way junction (3WJ) motif was recently
discovered (FIG. 6E-F) (Nature Nanotechnology, 2011;
Nano Today, 2012) [G9-10]. The 3WJ assembles from three
RNA oligos with unusually high affinity in the absence of
metal salts; is resistant to denaturation by 8 M urea; displays
thermodynamically stable properties; and does not dissociate at ultra-low concentrations (FIG. 7) [G9-12]. Without
being bound by theory, a melting curve with a slope close to

90° indicates an extremely low free energy (li.G) and cooperative assembly of the three component strands (FIG. 8).
2'-Fluoro (2'-F) modification [G9,G13,G56-58] resulted in
RNA nanoparticles resistant to RNase degradation, while
retaining authentic folding and biological activities [G9,
G10,G13] (FIG. 7D). Varieties of RNA nanoparticles were
constructed using the pRNA-3WJ as a scaffold and demonstrated that each functional module retained their folding
and independent functionalities for specific cell binding and
entry, gene silencing, and catalytic function in vitro and in
animal trials [G9-12] (FIG. 9-11). The pRNA-3WJ nanoparticles displayed favorable biodistribution and pharmacokinetic profiles, and avoided interferon responses and
cytokine production in mice [G12] (FIG. 25). The in vivo
half-life ofour 2'-F functional RNAs is 6-12 hr, compared to
0.25-0.75 hr of 2'-F bare siRNA [G12,G59,G60]. Recently
the crystal structure of the pRNA-3WJ core was obtained
[G14], which will facilitate the design of multifunctional
RNA nanoparticles.
RNA nanoparticles can be fabricated with a level of
simplicity characteristic of DNA, while possessing versatile
tertiary structures and catalytic functions that mimic some
proteins [G8,G49,G61-66]. RNA nanotechnology refers to
the design, fabrication, and application of RNA architectures
primarily made up of RNA via bottom-up self-assembly
(FIG. 9), in contrast to other widely studied drug delivery
systems conjugating functional RNA modules to polymer,
lipid, dendrimer, gold, or other nanomaterial based nanoparticles. Properties of the RNAnanoparticles created in the
presently disclosed subject matter include: (1) the body
treats RNA particles as its own, avoids phagocytosis by
macrophages and minimizes accumulation in normal
organs; (2) the polyanionic nature of RNA can avoid nonspecific cell entry since it is unfavorable for it to cross the
negatively charged cell membranes [G67-70]; (3) RNA is a
polymer (polynucleic acid). RNAnanoparticles have defined
size, structure, and stoichiometry (FIG. 9). Unpredictable
side effects from heterogeneous particles can thus be
avoided (FIG. 9) [GS-10, G20,G24]; (4) RNAnanoparticles
was designed that are 10-60 nm in size and sufficient to
harbor siRNAs, ribozymes, miRNAs, and aptamers (FIG. 9).
The nanoparticles are large enough to avoid renal excretion
(as is the case for bare siRNA), yet small enough to enter
cells by receptor-mediated endocytosis [71] and avoid
entrapment by liver Kupffer cells and lung macrophages
[G3,G8]; (5) the branched ratchet shape of our RNA nanoparticle design (FIG. 9) facilitates tumor penetration and
EPR (Enhanced Permeability and Retention) effects [G3,
GS]; (6) economic large scale production is possible in a
cell-free system; (7) RNA is highly soluble, not prone to
aggregation, and do not require linkage to PEG or serum
albumins [G8,G24], typically used for a wide range of
nanoparticles; (8) the multivalent nature of RNA nanoparticles allows integration of targeting, imaging and therapeutic modules for achieving synergistic effects without using
any cross-linking approaches (FIG. 9) [G8,G9] Modular
design allows self-assembly of engineered RNA fragments
[G8,G24]; (9) It has been demonstrated that 2'-F chemically
modified RNA is resistant to RNase degradation while
retaining authentic folding and biological functions [G9,
G10,G13]; (10) pRNA-3WJ nanoparticles are thermodynamically stable, and therefore will remain intact in vivo at
ultra-low concentrations (FIG. 7-8) [G9,G10]; (11) the
pRNA-3WJ based nanoparticles has favorable pharmacokinetic and pharmacodynamic profiles in vivo; is non-toxic
and does not induce interferon (FIG. 25) or cytokine production in mice [G9,G10,G12]; (12) systemic injection of

5

10

15

20

25

30

35

40

45

50

55

60

65

US 10,828,381 B2
13

14

the stable RNA nanoparticles into mice has revealed that
RNA nanoparticles strongly and specifically bind to cancers
with little accumulation in vital organs or tissues [G9,G10,
G12] (FIG. 11); (13) RNA nanoparticles do not induce
host-antibody responses, which will allow for repeated treatment of cancer. This is particularly applicable to patients
who develop neutralizing antibodies in response to proteinbased reagents; (14) RNA is a chemical reagent. Therefore,
the regulatory processes are expected to be more favorable
compared to protein-based clinical reagents [G8,G24].
In some embodiments, the presently disclosed subject
matter relates to an artificial RNA nanostructure molecule.
The molecule includes a RNA junction motif and at least one
imaging module. The RNA junction motif includes a plurality of branches, and a branch of the RNA junction motif
comprises at least one RNA oligonucleotide. In some
embodiments, the plurality of branches includes three
branches, four branches, five branches, six branches, seven
branches, eight or more branches (US 2014/0179758, herein
incorporated by reference by its entirety).
Nonlimiting examples of the imaging module includes
fluorescence dyes, radionuclides, and/or contrast agents.
Non-limiting examples of fluorescent dye include Alexa
dyes, Cy dyes or Near Infrared dyes. Further nonlimiting
examples of fluorescent dye include Alexa dye, Cy dyes,
Near Infrared (Near IR or NIR) dyes, including but not
limited to, IRdye 800 , Alexa 647 , Cy5, Cy5.5, Alexa680, Iowa
Black RQ, QSY21, IRDyeQC, BBQ650, BHQ-3, Indocyanine green (ICG). In some embodiments, the imaging module comprises a reporter imaging module. In some embodiments, the imaging module comprises a reference imaging
module. In some embodiments, the reference imaging module comprises a reference dye and a quencher. In some
embodiments, the RNA molecule further includes at least
one cancer targeting module coupled to the RNA junction
motif. In some embodiments, the molecule further includes
at least one therapeutic module coupled to the RNA junction
motif. In some embodiments, the imaging module is coupled
to at least one branch of the RNA junction motif. In some
embodiments, the imaging module is coupled to any branch
of the RNA junction motif. In some embodiments, the
imaging module is coupled to the cancer targeting module.
In some embodiments, the imaging module is coupled to the
therapeutic module. In one embodiment, the plurality of
branches comprising the RNA junction motif includes a
three-branched RNA junction motif. In one embodiment, the
plurality of branches comprising the RNA junction motif
comprises a four-branched RNA junction motif.
Also, as used herein, the term "couple," as used herein,
refers to the joining of two molecules together. Non-limiting
examples include a covalent attachment between an RNA
nanoparticle a ligand moieties such as folate, or of labeling
moieties, or of therapeutic agents, or by incorporation of
nuclease-resistant nucleotides (WO/2002/016596; U.S. Pat.
No. 7,655,787; WO/2005/003293; WO/2007/016507, which
are expressly incorporated by reference herein.)
NIR dyes or fluorophores are particularly attractive since
they can penetrate deep into tissues and more importantly,
auto-fluorescence from tissues is greatly reduced. without
being bound by theory, a robust RNA nanotechnology will
be developed utilizing the pRNA-3WJ motif for monitoring
the in vivo delivery of therapeutics non-invasively by NIRF
and PET/SPECT imaging. In some embodiments, the RNA
nanostructure molecule is used for in vivo imaging,
In some embodiment of the presently disclosed subject
matter, the RNA nanostructure includes a radionuclide. In
some embodiments, the term "radionuclide" includes radio-

label peptides and proteins with various isotopes. Nonlimiting examples of the radioisotopes includes 177Lu, 111 In,
64Cu, 99mTc, 203Pb, issRe, 212Pb/212Bi. In some embodiments, the radionuclide is coupled to more than one branch
of the RNA junction motif. In some embodiment, the
radionuclide is chelated by a chelating agent. In some
embodiments, the chelating agent is conjugated to at least
one branch of the RNA junction motif. Nonlimiting
examples of the chelating agent is EDTA, DOTA, NOTA.
In some embodiments, the RNA molecule includes a
contrast agent. The term "contrast agent," as used herein,
refers to a compound employed to improve the visibility of
internal body structures in an image, including but not
limited to, an X-ray image or a scanning image (e.g., CAT
(Computerized Axial Tomography) scan, MRI (Magnetic
Resonance Imaging) scan). The term contrast agent is also
referred to herein as a radiocontrast agent. Contrast agents
are employed in various diagnostic (e.g., cardiac catheterization) and therapeutic (e.g., vascular shunt placement)
procedures. Magnetic resonance imaging (MRI) is a powerful noninvasive technique that provides high quality three
dimensional images of tissues, including information on
anatomy, function, and metabolism of tissue in vivo. Gadolinium is a common T 1-weighted MRI contrast agent. In
some embodiments, the contract agent is a MRI contrast
agent. In some embodiments, the MRI contract agent is
gastrointestinal MRI, intravenous MRI, intravascular (blood
pool) MRI tumor-specific MRI, hepatobiliary MRI and
reticuloendothelial MRI. One non-limiting example of the
MRI contrast agent is a gadolinium contrast agent.
Biological macromolecules, as natural building blocks,
are critical for the functioning of living organisms. RNA is
one of the five most important biological macromolecules in
addition to DNA, proteins, lipids and carbohydrates. With
some aspects similar to DNA, RNA, composed of four
nucleotides including adenosine (A), cytosine (C), guanosine (G) and uridine (U), is special in its homogeneity. RNA
is a homopolymer of nucleotide, but is also a heteropolymer
of A, U, G, and C. Each nucleotide contains a ribose sugar,
a nucleobase, and a phosphate group. The nucleotides are
covalently linked together through 3'=5' phosphodiester
bonds between adjacent ribose units, giving the directionality to the sugar-phosphate backbone that defines RNA as
a polynucleic acid. The phosphate moieties in the backbone
are negatively charged, making RNA a polyanionic macromolecule at physiological pH. RNA molecules are typically
single-stranded; however, Watson-Crick (canonical) basepair interactions (A:U and G:C), wobble base pairing (such
as G:U) [G. Varani, W. H. McClain, EMBO Rep., 1 (2000),
pp. 18-23] or other non-canonical base pairing such as
twelve basic geometric families of edge-to-edge interaction
(Watson-Crick, Hoogsteen/CH or sugar edge) with the orientation of glycosidic bonds relative to the hydrogen bonds
(cis or trans) [U. Nagaswamy, et., al., Nucleic Acids Res., 30
(2002), pp. 395-397], all together give rise to various
structural conformations exhibiting loops, hairpins, bulges,
stems, pseudoknots, junctions, etc., which are essential
elements to guide and drive RNA molecules to assemble into
desired structures [Y. Xin, et al., RNA, 14 (2008), pp.
2465-2477; Y. Xin, et al., RNA, 14 (2008), pp. 2465-2477;
C. Laing, et al., PLoS ONE, 8 (2013), p. e71947; and C.
Laing, et al., Nucleic Acids Res., 40 (2012), pp. 487-498].
The characteristic of RNA that defines and differentiates
it from DNA is the 2'-hydroxyl on each ribose sugar of the
backbone. The 2'-OH group offers RNA a special property,
which can be either an advantage or a disadvantage. From a
structural point of view, the advantage of this additional
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hydroxyl group is that it locks the ribose sugar into a.
3'-endo chair conformation. As a result, it is structurally
favorable for the RNA double helix to adopt the A-form
which is -20% shorter and wider rather than the B-form that
is typically present in the DNA double helix. Moreover, the
2'-OH group in RNA is chemically active and is able to
initiate a nucleophilic attack on the adjacent 3' phosphodiester bond in an SN2 reaction. This cleaves the RNA
sugar-phosphate backbone and this chemical mechanism
underlies the basis of catalytic self-cleavage observed in
ribozymes. The disadvantage is that the 2'-OH group makes
the RNA susceptible to nuclease digestion since many
RNases recognize the structure of RNAs including the
2'-OH group as specific binding sites. However, such enzymatic instability has been overcome by applying chemical
modification of the 2'-OH group. For example, the substitution of the 2' hydroxyl group with a Fluorine (2'-F),
O-methyl (2'-O-Me) or Amine (2'-NH 2 ) dramatically
increases the stability of RNA in vivo by preventing degradation by RNases [48] [49 and [51]. Recent studies also
showed that the stability of siRNA in serum is also highly
depended on the specific RNA sequences and the degradation of both short and long RNA duplexes mostly occurred
at UA/UA or CA/UG sites [G 112] [Hui Li et al., Nanotoday,
volume 10, Issue 5, October 2015, pp 631-655, herein
incorporated by reference in its entirety].
In some embodiments, the nanostructure comprises at
least one chemical modification at a 2' position of the RNA
oligonucleotide. In some embodiments, the chemical modification comprises 2'Fluoro, 2'Amine, and 2'O-Methyl.
In some embodiments of the presently disclosed subject
matter, a branch of the three-branched RNA junction motif
is an a3WJ RNA module (SEQ ID NO: 1), a b3WJ RNA
module (SEQ ID NO: 2), or a c3WJ RNA module (SEQ ID
NO: 3). In one embodiment, the three-branched RNAjunction motif comprises an a3WJ RNA module (SEQ ID NO:
1), a b3 WJ RNA module (SEQ ID NO: 2), and a c3 WJ RNA
module (SEQ ID NO: 3). In some embodiments, SEQ ID
NO: 1 has at least 90% identity to nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3'. In one embodiment, SEQ ID NO: 1 comprises nucleotide sequence
5'-UUG CCA UGU GUA UGU GGG-3'. In some embodiments, SEQ ID NO: 2 has at least 90% identity to nucleotide
sequence 5'-CCCACA UAC UUU GUU GAUCC-3'. In one
embodiment, SEQ ID NO: 2 comprises nucleotide sequence
5'-CCC ACA UAC UUU GUU GAUCC-3'. In some
embodiments, SEQ ID NO: 3 has at least 90% identity to
nucleotide sequence 5'-GGA UCAAUC AUG GCAA-3'. In
one embodiment, SEQ ID NO: 3 comprises nucleotide
sequence 5'-GGA UCA AUC AUG GCA A-3'. In some
embodiments, the imaging module attaches to any one of the
a, b, and c module disclosed above. In some embodiments,
the targeting module attached to any one of the a, b, and c
module disclosed above. In some embodiments, the therapeutic module any one of the a, b, and c module disclosed
above.
In some embodiments of the presently disclosed subject
matter, the RNA nanostructure includes a cancer targeting
module. In some embodiments, the presently disclosed
subject matter provides that the targeting module in the
artificial RNA nano structure molecule includes a ligand that
binds to at least one cancer cell surface marker. In some
embodiments, the cancer targeting module is a colon cancer
targeting module.
As used herein, cell surface markers include any cellular
component that may be detected within or on the surface of
a cell, or a macromolecule bound or aggregated to the

surface of the cell. As such, cell surface markers are not
limited to markers physically on the surface of a cell. For
example, cell surface markers may include, but are not
limited to surface antigens, transmembrane receptors or
coreceptors, macromolecules bound to the surface, such as
bound or aggregated proteins or carbohydrates, internal
cellular components, and the like. Non-limiting examples of
the surface marker includes folate receptor, epithelial cell
adhesion molecule (EpCAM), EGFR, transferrin receptor,
and an RGD. In some embodiments, the ligand includes an
aptamer. In some embodiments, the aptamers binds against
EpCAM, EGFR (EGFR protein [Homo sapiens] GenBank:
AAI18666.1), PDGFR (platelet-derived growth factor
receptor beta precursor [Homo sapiens] NCBI Reference
Sequence: NP_002600.1), or folate receptor (folate receptor
[Homo sapiens] GenBank: AAB05827.1). In some embodiments, the targeting module is a folate.
The term "folate" as used herein can comprise a genus of
well-defined B-vitamin compounds, including but not limited to, 5-methyltetrahydro folate, 5-formyltetrahydrofolate,
dihydrofolate, tetrahydrofolate, folic acid and other folate
compounds. As disclosed herein, the targeted delivery systems call for a ligand-receptor pair that is specifically found
in cancer cells. Many cancer cells, including but not limited
to, stomach, ovary, lung, breast, kidney, endometrium, colon
and hematopoietic cells, over-expressed folate receptors
(FRs) than normal cells for high uptake of folate, since folate
is essential component during DNA replication and methylation in highly proliferating cells. Folic acid (FA), a
synthetic oxidized form of folate, has been widely used as a
ligand conjugate in various cancer targeting materials.
In some embodiments, the therapeutic module comprises
a siRNA, a miRNA, an anti-mRNA, a ribozyme RNA, or an
antisense RNA. In some embodiments, In some embodiments, the therapeutic module comprises a chemotherapeutic drug, a riboswitch, or an endosome disrupting agent. In
some embodiments, the therapeutic module is a siRNA
sequence. Non-limiting examples of the siRNA are siRNA
is directed to Survivin, Bcl-2, XIAP, BCL-XL, or BRCAAl.
In some embodiments, the siRNA directly binds to PI3K,
Akt, or mTOR. In some embodiments, the therapeutic
module is a microRNA sequence.
The terms "small interfering RNA", "short interfering
RNA", "small hairpin RNA", "siRNA", and shRNA are
used interchangeably and refer to any nucleic acid molecule
capable of mediating RNA interference (RNAi) or gene
silencing. See e.g., Bass, Nature 411 :428-429, 2001;
Elbashir et al., Nature 411 :494-498, 2001a; and PCT International Publication Nos. WO 00/44895, WO 01/36646,
WO 99/32619, WO 00/01846, WO 01/29058, WO
99/07409, and WO 00/44914. In one embodiment, the
siRNA comprises a double stranded polynucleotide molecule comprising complementary sense and antisense
regions, wherein the antisense region comprises a sequence
complementary to a region of a target nucleic acid molecule
(for example, a nucleic acid molecule encoding Survivin). In
another embodiment, the siRNA comprises a single stranded
polynucleotide having self-complementary sense and antisense regions, wherein the antisense region comprises a
sequence complementary to a region of a target nucleic acid
molecule. In another embodiment, the siRNA comprises a
single stranded polynucleotide having one or more loop
structures and a stem comprising self-complementary sense
and antisense regions, wherein the antisense region comprises a sequence complementary to a region of a target
nucleic acid molecule, and wherein the polynucleotide can
be processed either in vivo or in vitro to generate an active
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siRNA capable of mediating RNAi. As used herein, siRNA
molecules need not be limited to those molecules containing
only RNA, but further encompass chemically modified
nucleotides and non-nucleotides.
In some embodiments, the presently disclosed subject
matter takes advantage of the ability of short, double
stranded RNA molecules to cause the down regulation of
cellular genes, a process referred to as RNA interference. As
used herein, "RNA interference" (RNAi) refers to a process
of sequence-specific post-transcriptional gene silencing
mediated by a small interfering RNA (siRNA). See Fire et
al., Nature 391:806-811, 1998 and U.S. Pat. No. 6,506,559,
each of which is incorporated by reference herein in its
entirety. The process of post-transcriptional gene silencing is
thought to be an evolutionarily conserved cellular defense
mechanism that has evolved to prevent the expression of
foreign genes (Fire, Trends Genet 15:358-363, 1999).
Disclosed herein are non-limiting examples of siRNA
including Survivin-specific, Bcl-2, XIAP, and BCL-XL
siRNA sequences. The Survivin-specific siRNA includes
sense sequence: 5' GGACCACCGCAUCUCUACAdTdT 3'
(SEQ ID NO: 21) and antisense sequence: 5' dTdTCCUGGUGGCGUAGAGAUGU 3' (SEQ ID NO: 22) (See, e.g.,
Cancer Gene Ther. 2004 March; 11(3):186-93. Knockdown
of survivin expression by small interfering RNA reduces the
clonogenic survival of human sarcoma cell lines independently of p53.); the Bcl-2 siRNA includes sense sequence:
5'-AAGCUGuCACAGAGGGGCUAC-3' (SEQ ID NO:
23), and antisense sequence: 5'-GUAGCCCCUCUGUGACAGCUU-3 (SEQ ID NO: 24) (See, e.g., Nucleic
Acids Res. 2012 July; 40(13):6319-37. doi: 10.1093/nar/
gks294. Epub 2012 Mar. 30. Delivery of chemo-sensitizing
siRNAs to HER2+-breast cancer cells using RNA aptamers.); XIAP siRNA includes sense sequence: 5'-CCAUGUGCUAUACAGUCAUUACUUU-3 (SEQ ID NO: 25),
and antisense sequence: 5'-AAAGUAAUGACUGUAUAGCACAUGG-3 (SEQ ID NO: 26) (See, e.g., Mal Cancer.
2006 Sep. 5; 5:34. Specific down-regulation of XIAP with
RNA interference enhances the sensitivity of canine tumor
cell-lines to TRAIL and doxorubicin); and BCL-XL siRNA
includes sense sequence: 5'-UUGGACAAUGGACUGGUUGA-3 (SEQ ID NO: 27), antisense sequence:
5'-UCAACCAGUCCAUUGUCCAA-3 (SEQ ID NO: 28)
(See, e.g., Acta Biochim Biophys Sin (Shanghai). 2005
August; 37(8):555-60. Silencing of Bel-XL expression in
human MGC-803 gastric cancer cells by siRNA.) Further, in
one embodiment, siRNA is a BRCAAl siRNA. A nonlimiting example is a siRNA sequence 5'-CCACAUAAAGGGCCCACUA-3' (SEQ ID NO: 29). Another
non-limiting
example
is
a
siRNA
sequence
5'-UAGUGGGCCCUUUAUGUGG-3' (SEQ ID NO: 30).
In some embodiments, the bioactive agent is a microRNA
sequence. The term "Micro RNAs (miRNAs )" as used herein
are single-stranded, or double stranded non-coding RNAs, at
least about 6 nucleotide in length that can regulate gene
expression at the post-transcriptional level by either degrading their target mRNAs or inhibiting their translation(l,2).
MiRNAs play important roles in regulating cell cycle,
proliferation, differentiation, metabolism, and apoptosis(l).
A compendium of microRNA and respective microRNA
binding sequences is available at the miRNA registry. (See,
e.g., Griffiths-Jones et al. (2006) Nucl. Acids Res. 34:D140D144; US20140045709, herein incorporate by reference in
their entireties.) In particular embodiments, the microRNA
and microRNA binding sequence employed in the present
assay are associated with a disease or condition, wherein an

antagonist or agonist to the microRNA would be useful in
preventing or treating the disease or condition.
In some embodiments, the present disclosure provides
inhibitors of miRNAs (e.g., anti-miR-21). Compositions
comprising such inhibitors and methods for inhibiting miR21 using such inhibitors are also disclosed herein. Any
miRNA inhibitor may be used alone, or with other miRNA
inhibitor(s) known in the art. In some embodiments, the
miRNA inhibitor comprises an antisense molecule. In some
embodiments, the antisense molecule could be a single or a
double stranded sequence. Examples of antisense molecule
include, but are not limited to, siRNAs, triple-helix-forming
agents, ribozymes, RNAi, synthetic peptide nucleic acids
(PNAs), antigens (agRNAs), LNA/DNA copolymers, small
molecule chemical compounds, and antisense oligonucleotides.
In some embodiments, the microRNA sequence is at least
6 nucleotide in length. In some embodiments, the miRNA
molecule or an equivalent, or a mimic thereof is from about
6 to about 30 nucleotides in length. In some embodiments,
the miRNA is about 12 to about 30 nucleotides in length. In
some embodiments, the miRNA is from about 15 to about 28
nucleotides in length. In some embodiments, the miRNA is
about 19 to about 25 nucleotides in length. In some embodiments, the miRNA molecule has a length of at least about 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, about 30 nucleotides or more. In some
embodiments, an antagomir of a miRNA molecule is from
about 6 to about 30 nucleotides in length, from about 10 to
about 30 nucleotides in length, from about 12 to about 28
nucleotides in length. In some embodiments, the antagomir
of a miRNA molecule has a length of at least about 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 27, 28, 29, about 30 nucleotides or more.
In some embodiments, the miRNA interferes oncogenic
miRNA to regress cancer growth. The RNA nanostructure
molecule contains anti-miRNA that silences oncogenic miRNAs, including but not limited to, miR-9, miR-l0b, miR-21,
miR-17, and miR-26. In some embodiments, the miRNA
rescues down-regulated cancer suppressive miRNAs, where
the RNA nanostructure introduces cancer suppressive miRNAs, including but not limited to, let-7a, miR-l0b, miR-25,
miR-34a, miR-124, miR-145, and miR-181b. Further
examples is disclosed in US20140045709, which herein
incorporate by reference in its entirety.
In some embodiments, the therapeutic module is a cytotoxic drug. The terms "cytotoxic drug" used herein refers to
agents that have the property of inhibiting the growth or
proliferation (e.g., a cytostatic agent), or inducing the killing, of hyper proliferative cells. Non-limiting examples
include doxorubicin, paclitaxel, paclitaxel derivatives and
analogues, cytochalasin D, rapamycin, rapamycin derivatives and analogues, camptothecin, dexamethasone, and
5-fluorouracil, a quinazolinone derivative, metallic silver,
tranilast, everolimus and related compounds, or other agents
that inhibit cell proliferation and or migration and/or inflammatory processes.
In another aspect, the presently disclosed subject matter
provides an artificial RNA nanostructure molecule includes
a RNA junction motif comprising a plurality of branches and
a radiation-based therapeutic module coupled to the RNA
junction motif, and a branch of the RNA junction motif
includes at least one RNA oligonucleotide. In some embodiments, the molecule further includes a cancer targeting
module coupled to the RNA junction motif. In some embodiments, the molecule further includes an imaging module
coupled to the RNA junction motif. In some embodiments,
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the nanostructure comprises at least one chemical modification at 2' position of the RNA oligonucleotide. In some
embodiments, the chemical modification comprises
2'Fluoro, 2'Amine, and 2'O-Methyl. In some embodiments,
the plurality of branches comprises three branches, four
branches, five branches, six branches, seven branches, eight
or more branches. In some embodiments, the plurality of
branches comprising the RNA junction motif includes a
three-branched RNA junction motif. In some embodiments,
the plurality of branches comprising the RNA junction motif
comprises a four-branched RNA junction motif. In some
embodiments, a branch of the three-branched RNA junction
motif includes an a3WJ RNA module (SEQ ID NO: 1), a
b3WJ RNA module (SEQ ID NO: 2), or a c3WJ RNA
module (SEQ ID NO: 3). In some embodiments, the threebranched RNA junction motif comprises an a3WJ RNA
module (SEQ ID NO: 1), a b3WJ RNA module (SEQ ID
NO: 2), and a c3WJ RNA module (SEQ ID NO: 3). In some
embodiments, SEQ ID NO: 1 has at least 90% identity to
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG3'. In some embodiments, SEQ ID NO: 1 comprises nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG-3'. In
some embodiments, SEQ ID NO: 2 has at least 90% identity
to nucleotide sequence 5'-CCC ACA UAC UUU GUU
GAUCC-3'. In some embodiments, SEQ ID NO: 2 comprises nucleotide sequence 5'-CCC ACA UAC UUU GUU
GAUCC-3'. In some embodiments, SEQ ID NO: 3 has at
least 90% identity to nucleotide sequence 5'-GGA UCA
AUC AUG GCAA-3'. In some embodiments, SEQ ID NO:
3 comprises nucleotide sequence 5'-GGA UCA AUC AUG
GCAA-3'. In some embodiments, the cancer-targeting module is a cancer cell-specific ligand. In some embodiments,
the cancer-targeting module is folate. In some embodiments,
cancer-targeting module is an RNA aptamer. In some
embodiments, the radiation-based therapeutic module
include a isotope. Nonlimiting examples of the isotope
include 177Lu, lllln, 64Cu, 99mTc, 203Pb, 188Re, 212Pb,
212Bi, I-125, or Cs-131. In some embodiments, the RNA
nanoparticles derived from the pRNA 3WJ are substantially
stable under irradiation with clinically relevant doses ranging from about 1 Gy, 5 Gy, 10 Gy, 15 Gy, 20 Gy, 25 Gy, 30
Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, 60 Gy, 65 Gy, 70
Gy, 75 Gy, 80 Gy, 85 Gy, to about 90 Gy.
Cancer is a broad class of diseases featuring uncontrollable cell growth, invasion, and destruction of nearby tissues
and metastasis. An effective, efficient, and safe treatment for
cancer is urgently needed. Radiation therapy represents a
major modality for anticancer therapy, which utilizes ionizing radiation produced by linear accelerators (external beam
therapy) or radioactive isotopes (brachytherapy and nuclear
medicine) to kill cancer cells, inhibit tumor growth, and
prevent recurrence of the tumor [5]. However, radiation not
only kills cancer cells, but also damages healthy cells. The
side effects associated with current radiation therapy significantly limit the doses delivered to the patients [6, 7]. The
goal of radiation therapy is to deliver a high dose of radiation
to the target to kill cancer cells while sparing the surrounding healthy tissues. But, this is not easy to achieve using
current techniques. Medical imaging including CT and MRI
is used to accurately identify and locate or track tumor
before, during and even after treatment. Since such imaging
can only recognize balky lesions, it is very difficult to find
and locate all the cancer cells especially microscopic disease. In addition to that, it is also very difficult to avoid
normal tissue damages during dose delivery. External beam
therapy uses ionization particles that may have to pass
through the normal tissue before reaching the target. Brachy-

therapy handles radiation sources mechanically and has
significant uncertainty in localizing the radioactive sources.
Although certain ionizing radiopharmaceuticals, such as
I-131 and Y-90 used in nuclear medicine, can target certain
organs and tumors, variation in biodistribution caused by
metabolism and excretion of the pharmaceuticals and localization errors produce uncertainties and limitations in targeting tumor and dosimetry, and thus increase damages to
normal tissues [8].
The RNA nanoparticle-based nano-carrier platform can
overcome aforementioned limitations for conventional
radiation therapy and diagnosis and opens new opportunities
for specific delivering radiation to cancer without damaging
healthy organs and tissues, reducing the toxicity and side
effect, improving the therapeutic effect, and exhibiting great
potential in clinical cancer therapy and diagnosis.
Recently, nanoparticles have been found to be able to
accurately target cancer cells and thus, can be used for
cancer targeting and treatment [9-14]. Nanoparticles are
typically within several hundred nanometers in size, and
comparable to large biological molecules such as enzymes,
receptors, and antibodies. Because of small size, nanoparticles can interact with biomolecules both on the surface of
and inside the cells, participate in molecular, biochemical,
and biological processes, and thus, can be used as agents for
medical imaging and targeted cancer treatment [15]. The
most common well-studied nanoparticles include quantum
dots, carbon nanotubes, paramagnetic nanoparticles, liposomes, gold nanoparticles, and many others. However, there
are concerns regarding the biocompatibility of these nanoparticles especially when they are exposed to radiation and
their ability to escape the reticuloendothelial system, which
could lead to short- and long-term toxicity [16, 17].
A new discovery in nanotechnology has led to the development of novel RNA nanoparticles that are mainly composed of RNA that are capable of strongly binding to tumors
without accumulation in other vital organs or tissues [1820]. Since the first proof-of-concept in 1998 [21], RNA
nanotechnology has emerged as a popular and rapidlygrowing field that is at the interface of nanotechnology,
molecular biology, medicine, and biomedical engineering
[13, 20, 22-26]. RNA nanotechnology holds significant
translational potential in medicine and features that could
make RNA nanoparticles desired pharmaceutical agents and
radioisotope carriers. First of all, RNA nanoparticles can be
produced with a known stoichiometry with a high reproducibility [21, 26, 27]. The simplicity of RNA, being composed
of only four nucleic acid bases, allows for predictable and
addressable formation of various nanostructures harboring
different functional groups by bottom-up self-assembly. Secondly, RNA nanoparticles can target specific cell groups by
targeting cell surface receptors through the use of RNA
aptamers that function like protein or chemical ligands [18,
28, 29]. These structures do not induce antibody production,
allowing for repeated delivery and therapy [28]. Thirdly,
RNA nanoparticles that have been produced have a size
range of 10-50 nm, which is the perfect size not only to be
retained within the body by avoiding rapid renal excretion,
but also to pass through leaky blood vessels in cancer
tumors, as well as cell membranes, by cell surface receptormediated endocytosis [18-20].
To have clinical applications, RNA nanoparticles and
those properties must remain stable and unchanged under
the clinical conditions. The bacteriophage phi29 packaging
RNA (pRNA) represents an attractive platform for bottomup assembly of RNA nanoparticles [18-20, which are incorporated by reference by their entirety]. The molecular struc-
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ture of pRNA contains a helix domain, a central domain
containing right and left-hand loops, and a three-way junction (3WJ) core [30]. A recent study has indicated that the
pRNA 3WJ has thermodynamical stability, and RNA nanoparticles constructed based on the pRNA 3WJ core are also
thermodynamically and chemically stable [27]. In addition,
a receptor-binding ligand, an aptamer, a short interfering
RNA and a ribozyme can be incorporated in the pRNA 3WJ
nanoparticle and retain their correct folding and function.
The pRNA nanoparticles also display a favorable pharmacokinetics profile for in vivo target delivery (half-life of 5-10
hr compared to 0.25-0.75 hr of 2'F siRNA counterparts) [28,
which is incorporated by reference in its entirety]. To be
used as radioisotope carriers, the stability of RNA nanoparticles will be further tested under irradiation with clinically
relevant doses.
In some embodiments, the molecule is substantially stable
under radiation treatment. As used herein, the term "substantially stable" can refer to physical and/or chemical
stability. As will be recognized by those of ordinary skill in
the art, the term "substantially stable" can refer to stability
of the composition under certain conditions, relative to an
initial composition (i.e., when a particular batch of the
composition is initially prepared). In this regard, as will be
recognized by those of ordinary skill in the art, one manner
in which stability of a particular embodiment of the composition can be determined is as follows: preparing a batch
of the embodiment of the composition, making an initial
assessment of a sample of the composition (control sample),
subjecting a sample of the composition to conditions of
interest (e.g., storage at a particular temperature for a
particular time period) (test sample), making an assessment
of the test sample, and comparing the assessment of the
control sample to the assessment of the test sample. Calculations can be made to determine whether the amounts
present in the test sample are 100%±20, 19, 18, 17, 16, 15,
14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.5, or 0.1 % of the
amount that is in the control sample.
In one embodiment, the present disclosure proposes to use
the 3WJ RNA nanoparticles to carry radioisotope. In one
embodiment, the present disclosure proposes to use a fourway junction (4WJ) RNA nanoparticles to carry radioisotope. Non limiting examples of the radioisotope are I-125 or
Cs-131. Using such RNA nanoparticles, cancer cells can be
targeted and treated by I-125 or Cs-131 [31]. In nuclear
medicine, several radioactive isotopes, such as I-131, P-32,
and Y-90, have been used for targeted radionuclide therapy,
but those isotopes are only applied to very limited types of
cancer [32-36]. Also, most of isotopes used for nuclear
medicine therapy are beta emitters and not suitable for
imaging. Accurate dose estimation is almost impossible
without accurate imaging. On the other hand, I-125 and
Cs-131 have been widely used in permanent implant brachytherapy and successfully treated various types of cancer. The
idea of using I-125 or Cs-131 with 3WJ RNAnanoparticles
is to increase the accuracy of tumor targeting and enhance
the effectiveness in treating a broad range of tumors and
sparing normal tissues. Also, both I-125 and Cs-131 emit
photons that will help with in vivo nuclear imaging and
studying the biodistribution of those isotopes for estimation
of patient-specific dose. The stabilities of the pRNA 3WJ
nanoparticles that are essential for in vivo cancer targeting
and treatment are investigated in this study.
This study further investigates whether chemically modified RNA nanoparticles derived from pRNA Three-Way
Junction (3 WJ) of phi29 DNA-packaging motor are resistant
to potent I-125 and Cs-131 radiation, which is a required

perquisite for utilizing these RNA nanoparticles as carriers
for targeted radiation therapy. pRNA 3WJ nanoparticles
were constructed and characterized and the stability of these
nanoparticles under I-125 and Cs-131 irradiation with clinically relevant doses was examined. RNA nanoparticles
derived from the pRNA 3WJ targeted tumors specifically
and they were stable under irradiation ofI-125 and Cs-131
with clinically relevant doses ranging from about 1 Gy to
about 90 Gy over a significantly long time up to 20 days,
while control plasmid DNA was damaged at 20 Gy or
higher.
The RNA nanoparticle-based nano-carrier platform for
radiation therapy and diagnosis is expected to outperform
current radiation systems or other strategies in several
aspects: (1) RNA nanoparticles have defined size, structure
and stoichiometry; unpredictable side effects arising from
heterogeneous particles can thus be avoided; (2) nanoscale
size of the RNA nanoparticles will facilitate tissue penetration and target to tumor; (3) RNA nanoparticles are easy to
construct by self-assembly, highly soluble and not prone to
aggregation; (4) the RNA nanoparticles are thermodynamically stable and, therefore, the entire construct will remain
intact at ultra-low concentrations in the body; (5) the polyvalent nature of the RNA nanoparticle allows for easy
integration of targeting modules, imaging modules and
therapeutic modules into a single form; (6) RNA nanoparticles display low or no immunogenicity and/or toxicity even
at high doses. The 3WJ-pRNA scaffold displays favorable
pharmacokinetic and pharmacodynamic profiles in vivo
(half-life of 5-10 hours compared to 0.25-0.75 hours of the
most stable 2'F modified siRNA counterparts); non-toxic;
and no induction of interferon or cytokines; (7) systemic
injection of the thermodynamically and chemically stable
RNA nanoparticles into the tail-vein of mice revealed that
the RNA nanoparticles remain intact. They strongly and
specifically bind to cancers without entering liver, lung, or
any other vital organs or tissues. This is particularly an
advantage for targeting solid tumors previously inaccessible
due to penetration problems through the vasculature and
dispersion against an interstitial pressure; (8) RNA nanoparticles derived from the pRNA 3WJ are stable under
irradiation of I-125 and Cs-131 with clinically relevant
doses ranging from 1 Gy to 90 Gy over a significantly long
time up to 20 days.
Further, in another aspect of the present subject matter, a
RNA dendrimer molecule is provided. The molecule
includes (a) a central core multi-branched RNA junction
motif, wherein the central core motif comprises a plurality
of branches, and wherein a branch comprises at least one
RNA oligonucleotide; and (b) an outer surface multibranched RNA junction motif comprising at least one
repeating multi-branched RNA junction motif unit, wherein
the repeating unit comprises a plurality of branches, and
wherein a branch comprises at least one RNA oligonucleotide. In some embodiments, the dendrimer further includes
at least one imaging module. In some embodiments, the
dendrimer includes at least one targeting module. In some
embodiments, the dendrimer further includes at least one
therapeutic module. In some embodiments, the plurality of
branches includes the central core multi-branched RNA
junction motif comprises a three-branched RNA junction
motif, a four-branched RNA junction motif, a five-branched
RNA junction motif, a six-branched RNA junction motif, a
seven-branched RNA junction motif, an eight or more
branched RNA junction motif. In some embodiments, the
plurality of branches comprising the repeating multibranched RNA junction motif unit includes a three-branched
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RNA junction motif, a four-branched RNA junction motif, a
five-branched RNA junction motif, a six-branched RNA
junction motif, a seven-branched RNA junction motif, an
eight or more branched RNA junction motif. In some
embodiments, a branch of the three-branched RNA junction
motif comprises an a3 WJ RNA module (SEQ ID NO: 1); a
b3WJ RNA module (SEQ ID NO: 2); or a c3WJ RNA
module (SEQ ID NO: 3). In one embodiments, the threebranched RNA junction motif comprises an a3WJ RNA
module (SEQ ID NO: 1); a b3WJ RNA module (SEQ ID
NO: 2); and a c3WJ RNA module (SEQ ID NO: 3). In some
embodiments, SEQ ID NO: 1 has at least 90% identity to
nucleotide sequence 5'-UUG CCA UGU GUA UGU GGG3'. In some embodiments, SEQ ID NO: 2 has at least 90%
identity to nucleotide sequence 5'-CCC ACA UAC UUU
GUU GAUCC-3'. In some embodiments, SEQ ID NO: 3 has
at least 90% identity to nucleotide sequence 5'-GGA UCA
AUC AUG GCA A-3'. In some embodiments, the central
core multi-branched RNA junction motif is a polygon
shaped architecture comprising a three-branched RNAjunction motif at each comer. In some embodiments, the imaging
module comprises a fluorescent dye, a radionuclide, or a
contrast agent. In some embodiments, fluorescent dye is a
Alexa dye, Cy dyes or Near IR dyes. Nonlimiting of
fluorescent dye include IRdye800, Alexa647, Cy5, Cy5.5,
Alexa680, Iowa Black RQ, QSY21, IRDyeQC, BBQ650,
BHQ-3, Indocyanine green (ICG). In some embodiments,
the imaging module comprises a reporter imaging module.
In some embodiments, the imaging module comprises a
reference imaging module. In some embodiments, the reference imaging module comprises a reference dye and a
quencher. In some embodiments, the imaging module comprises at least one fluorescent dye. In some embodiments,
the imaging module include a radionuclide and/or a contrast
agent. A nonlimiting example of contrast agent is a MRI
contrast agent. In one embodiment, the imaging module
includes at least one gadolinium contrast agent. In some
embodiments, the targeting module includes a cancer targeting module. In some embodiments, the cancer targeting
module is a ligand that binds to at least one cancer cell
surface marker. In some embodiments, the RNA dendrimer
contains a targeting module comprises a chemical ligand
and/or a RNA aptamer. A nonlimiting example of the ligand
includes folate. In some embodiments, the cell surface
markers comprises a folate receptor. In some embodiments,
the ligand binds to an epithelial cell adhesion molecule
(EpCAM). In some embodiments, the cell surface marker
comprises an epithelial cell adhesion molecule (EpCAM). In
some embodiments, the cancer targeting module comprises
an aptamer. A non-limiting example of the aptamer is an
EpCAM RNA aptamer. In some embodiments, the cancer
targeting module is a folate. Nonlimiting examples of the
folate include folic acid, 5-methyltetrahydro folate, 5-formyltetrahydrofolate, dihydrofolate, tetrahydrofolate, or a
combination thereof. In some embodiments, the therapeutic
module comprises a siRNA, a miRNA, an anti-mRNA, a
ribozyme RNA, or an antisense RNA. In some embodiments, the therapeutic module comprises a chemotherapeutic drug, a riboswitch, or an endosome disrupting agent. In
some embodiments, the therapeutic module is a cytotoxic
drug. Nonlimiting examples of the cytotoxic drug include
doxorubicin, paclitaxel, paclitaxel derivatives and analogues, cytochalasin D, rapamycin, rapamycin derivatives
and analogues, camptothecin, dexamethasone, and 5-fluorouracil, a quinazolinone derivative, metallic silver, tranilast, everolimus and related compounds, or other agents that
inhibit cell proliferation and or migration and/or inflamma-

tory processes. In some embodiments, the plurality of
branches of the multi-branched comprises at least 90%
identity to nucleotide sequences of at least one of SEQ ID
NOS: 1-20.
In recent years, extensively branched 3D structures called
dendrimers[Dl-3] have become an attractive platform for
building multifunctional macromolecular nanomaterials as
diagnostic and therapeutic agents[D4-8]. This is primarily
because of the polyvalent nature, nanoscale size, highly
branched, and void-space containing framework of dendrimers, which offers high loading capacity of desired functionalities. The attractive and intriguing dendrimers were conceptualized over four decades ago[Gl]; however,
improvements are desirable for realizing their commercial
availability in clinical settings. For example, the multi-step
synthetic reactions necessary to generate defect-free dendrimer that impact product yield and purity. Incorporation of
different functional modules to generate a multifunctional
framework often requires series of protection-deprotection
steps that affects synthetic yield, water solubility and even
functionality. Traditional small molecule building blocks,
such as high molecular weight carrier poly(amidoamine)
(PAMAM) and poly (propyleneimine) (PPI) dendrimers are
mostly smaller than 10 nm with angstrom level size differences within successive generations, make it desirable to
seek alternate building blocks to enhance their size in order
to avoid rapid renal clearance for in vivo applications.
Larger building blocks such as nucleic acids can overcome the size limitation. The self-assembly properties of
nucleic acids can prevail over the complex synthetic routes
to generate precisely assembled dendrimers under control. It
has been proposed that DNA can serve as building blocks
[D3], and the construction of DNA dendrimers by enzymatic
ligation[D9], and recently, by hybridization using sticky end
segments [D6,D10-13] have been reported. RNA dendrimers have not been realized to date due to challenges in
predicting intra- and inter-molecular RNA folding involving
canonical and non-canonical base pairing, base stacking, and
tertiary interactions[D14,D15], as well as concerns regarding the chemical stability of RNA[Dl 6-18].
Recent progress in RNA nanotechnology has enabled
construction of varieties ofRNAnanostructures with precise
control of size, shape and stoichiometry[D16-21]. Several
structural RNA motifs have been used as scaffold to construct varieties of 2D and 3D architectures including,
branched RNA nanoparticles[D22-24], packaging RNA
(pRNA) hexamers [D24,D25], nanorings [D26,D27], triangles [D28,D29], square[D30-32], pentagons[D33]; cube
[D34], and origami structures[D35]. Recently we discovered
a robust 3WJ (three-way junction) motif derived from
pRNA[D36] of the phi29 bacteriophage DNA packaging
motor[D22] that can serve as a scaffold for fabricating RNA
nanoparticles. The pRNA-3WJ assembles from three pieces
of RNA oligonucleotides, is unusually thermodynamically
stable (Tm of 59° C.; llG 0 37 " c. of -28 kcal/mo!), is resistant
to denaturation even in presence of 8 M urea, and remains
intact at ultra-low concentrations in vivo[D22,23,37]. We
have functionalized the pRNA-3WJ with targeting, imaging
and therapeutic modules, and the resulting RNA nanoparticles have been used for cancer targeting[D22-24,D38-40]
and therapy[D41,D42], as well as for resistive biomemory
applications [D43]. More recently, we solved the crystal
structure of the pRNA-3WJ scaffold[D44], which has facilitated the designs of multifunctional RNA nanoparticles.
RNA has also been reported as a boiling-resistant anionic
polymer material to build robust structures with defined
shape and stoichiometry[D28,D45].
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As disclosed herein, the presently disclosed subject matter
provides the construction of RNA dendrimers utilizing the
highly stable pRNA-3WJ motif as core scaffold. Each of the
component strands were synthesized by transcription or
chemically using phosphoramidite chemistry and then selfassembled sequentially to construct 3D globular Generation0-4 (G-O-G-4) RNA dendrimers. The assembly of RNA
dendrimers employs modular design principles and is highly
controllable. Functional groups can be introduced with
relative ease both internally as well as at the peripheral ends
of the component strands prior to the assembly process, thus
resulting in homogenous (monodisperse) RNA dendrimers
with high yield and purity.
As disclosed herein, RNA dendrimers have the following
features: (1) monodisperse; (2) polyanionic nature; (3) tunable shape with defined 3D structure (GO-G3); (4) tunable
nanoscale size (5-100 nm) (GO-G3); (5) polyvalent nature
that allows conjugation of multiple therapeutic payloads and
detection modules without any cross-linking; (6) large number of readily accessible terminal functional groups; (7)
modular design that allows self-assembly of engineered
RNA fragments; (8) biocompatible; (9) thermodynamic
stable; hence, the entire construct will remain intact at
ultra-low concentrations in the body; (10) chemically stable,
after 2'-F modifications and therefore resistant to RNase
degradation while retaining correct folding and biological
functions; (11) longer plasma half-life using chemically
modified RNA; (12) reproducible manufacturing framework
for generating homogenous RNA nanoparticles, which
avoids immune responses and non-specific side effects; (13)
economic industrial scale production is possible in a cellfree system; (14) highly soluble and not prone to aggregation. They do not require any additional steps, such as
linkage to PEG or serum albumins; (15) display low or no
immunogenicity and/or toxicity even at high doses; (16)
displays favorable pharmacokinetic and pharmacodynamic
profiles in vivo (half-life of 5-10 hrs compared to 0.25-0.75
hrs of 2'F siRNA counterparts) in mice; (17) systemic
injection of the thermodynamically and chemically stable
RNA nanoparticles into mice revealed that the RNA nanoparticles strongly and specifically bind to cancers without
accumulating in liver, lung, or any other vital organs or
tissues; (18) minimal induction of antibody production will
allow for repeated treatment of cancer. This is particularly
applicable to patients who develop neutralizing antibodies to
the protein-based reagents following repeated administrations.
As disclosed herein, RNA as construction material for
fabricating GO, Gl, G2 andG3 dendrimers. In some embodiments, RNA dendrimers harbor cytotoxic drugs (hydrophilic
and hydrophobic) to kill tumors in a controlled and sustained
manner. In some embodiments, RNA dendrimers harbor
siRNA to knockdown genes involved in disease progression.
In some embodiments, RNA dendrimers harbor anti-miRNA
to knock-down oncogenic genes. In some embodiments,
RNA dendrimers harbor miRNA to increase the endogenous
tumor-suppressor miRNA. In some embodiments, RNA
dendrimers harbors aptamers or chemical ligands for binding to cell surface receptors. In some embodiments, RNA
dendrimers harbor aptamers or chemical ligands for internalization of RNA dendrimers into target cells via endocytosis. In some embodiments, RNA dendrimers harbor
ribozymes for cleaving target substrates. In some embodiments, RNA dendrimers harbor riboswitch for modulating
cellular pathways in response to stimuli. In some embodiments, RNA dendrimers harbor multiple MRI contrast
agents. In some embodiments, RNA dendrimers harbor

multiple CT contrast agents, multiple PET tracers, multiple
NIR imaging agents. In some embodiments, RNA dendrimers harboring radioactive isotopes for disease detection. In
some embodiments, RNA dendrimers carry electropositive
proton sponge reagents such as imidazoles or amines for
endosome escape, and electronegative therapeutic RNA
such as siRNA, miRNA, riboswitch, and ribozyme for
therapy of cancers and other diseases including disease
diagnosis including, but not limited to cancer, immunology,
respiratory, central nervous system, inflammatory, and infectious diseases. In some embodiments, RNA dendrimer is
used for transdermal drug delivery, oral drug delivery, ocular
drug delivery, pulmonary drug delivery, tissue engineering
and organ scaffolding. In some embodiments, RNA dendrimer is used for disease treatment, including, but not
limited to cancer, immunology, respiratory, central nervous
system, inflammatory, and infectious diseases. In some
embodiments, RNA dendrimers are used for disease diagnosis including, but not limited to cancer, immunology,
respiratory, central nervous system, inflammatory, and infectious diseases.
In another aspect of the presently disclosed subject matter,
is a composition comprising a therapeutically effective
amount of the RNA nanostructure molecule and RNA dendrimer as disclosed above and herein. In some embodiments,
the composition further includes a pharmaceutically acceptable carrier.
Yet in another aspect of the presently disclosed subject
matter, is a drug delivery system, the system comprising a
therapeutically effective amount of the RNA nanostructure
and the RNA dendrimer molecule as disclosed above and
herein. In some embodiments, drug delivery system further
includes a pharmaceutically acceptable carrier.
Further, in some embodiments, the presently disclosed
subject matter provide a method of image-guided drug
delivery of a therapeutic agent to a subject in need thereof.
The method include administering a therapeutically effective amount of RNA nanostructure molecule and RNA
dendrimer as disclosed above and herein, and applying an
imaging detection apparatus to the subject. In some embodiments, the imaging detection apparatus is an MRI imaging
system. In some embodiments, the imaging detection apparatus is an NIRF imaging system. In some embodiments, the
imaging detection apparatus is an CT/PET/SPECT imaging
system.
Development of image-guided drug delivery systems for
real-time monitoring, and validating the effect of delivery
and response is very important for research and clinical
applications[Gl]. In the last decade, multifunctional nanoparticles of varying materials and physiochemical properties
have been pursued as imaging and therapeutic platforms;
however, effective strategies to quantitatively evaluate delivery of therapeutic payloads to tumors and metastatic cancer
cells are challenging due to low efficiency in specific cancer
targeting, non-specific accumulation in vital organs such as,
liver and lungs, particle heterogeneity, dissociation after
systemic injection due to dilution, and unfavorable pharmacokinetic and pharmacodynamic profiles [G 1-7]. The goal is
to adopt an innovative RNA nanotechnology approach (The
Emerging Field of RNA Nanotechnology, Nature Nanotechnology 2010, 5:833)[G8] to construct ultrastable multifunctional RNA Beacons and RNA Dendrimers for quantitative
assessment of tumor and metastatic cancer targeted therapeutic delivery, distribution, uptake and response. As
reported in recent publications [G9-23], the RNA constructs
are non-toxic, non-immunogenic and capable of penetrating
across heterogeneous biological barriers to deliver high
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doses of therapeutics to solid tumors and metastatic cells in
mice with little accumulation in normal organs and tissues
[G9-23]. This provides an ideal system to non-invasively
image delivery of cancer therapeutics in vivo.
The presently disclosed subject matter will employ multimodal imaging techniques (NIRF, PET/SPECT and/or
MRI) that provide anatomic and quantitative functional
measures of the drug delivery process at various spatial and
temporal resolutions in real-time. This approach is based on
the consideration that each of these three modalities has
advantages, and an integrated approach will lead to synergistic imaging benefits. For instance, MRI using contrast
agents harbored in RNA Dendrimers and RNA Beacons
(FIG. 4-5) offers a high spatial resolution and can provide a
better description of the particle distribution pattern than
either PET or NIRF. PET provides a better signal-to-noise
ratio because of the use of radiotracers. NIRF, on the other
hand, can be visualized both in vivo by an IVIS system and
ex vivo, by fluorescence microscopy, playing a unique role
of bridging the in vivo and histological observations.
In some embodiments, the presently disclosed subject
matter provides a kit for detecting, determining and/or
localizing a biological substances of interest. The kit
includes a RNA nanostructure and/or a RNA dendrimer as
disclosed herein. In some embodiments, the kit further
included a suitable means of detection. In some embodiments, the kit includes the RNA-3WJ-Beacon as disclosed
herein. Non-limiting examples of suitable means of detection include MRI, nuclear imaging (e.g. PET or SPECT),
optical imaging, sonoluminence imaging or photoacoustic
imaging (ultrasound). The skilled in the art will appreciate
that the particular imaging module of the present disclosure
should be compatible with the particular imaging modality
being used.
In some embodiments, the presently disclosed subject
matter provides a method of diagnosing and/or treating a
disease in a subject having or at risk of having the disease,
the method comprising administering to the subject a therapeutically effective amount of a composition comprising a
RNA nanostructure molecule and RNA dendrimer as disclosed above and herein. In some embodiments, the composition further comprises a pharmaceutically acceptable
carrier. In some embodiments, the subject is a manimal or a
non-mammal vertebrate. In some embodiments, the subject
is a human. In some embodiments, the disease is a cancer.
In some embodiments, the cancer is a colon cancer. Nonlimiting examples of the disease include cancer, immunology, respiratory, central nervous system, inflammatory, and
infectious diseases. Non-limiting examples of a cancer
include but not limited to ovarian cancer, brain cancer, bone
cancer, lung cancer, colorectal cancer.
The term "pharmaceutically acceptable carrier" as used
herein refers to a diluent, adjuvant, excipient, or vehicle with
which a heterodimeric probe of the disclosure is administered and which is approved by a regulatory agency of the
federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use
in animals, and more particularly in humans. Such pharmaceutical carriers can be liquids, such as water and oils,
including those of petroleum, animal, vegetable, or synthetic
origin, such as peanut oil, soybean oil, mineral oil, sesame
oil, and the like. The pharmaceutical carriers can be saline,
gum acacia, gelatin, starch paste, talc, keratin, colloidal
silica, urea, and the like. When administered to a patient, the
heterodimeric probe and pharmaceutically acceptable carriers can be sterile. Water is a useful carrier when the
heterodimeric probe is administered intravenously. Saline

solutions and aqueous dextrose and glycerol solutions can
also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include
excipients such as glucose, lactose, sucrose, glycerol monostearate, sodium chloride, glycerol, propylene, glycol, water,
ethanol, and the like. The present compositions, if desired,
can also contain minor amounts of wetting or emulsifying
agents, or pH buffering agents. The present compositions
advantageously may take the form of solutions, emulsion,
sustained release formulations, or any other form suitable for
use.
The term "therapeutically effective amount," as used
herein, refers to the amount of a composition containing
administered to a patient already suffering from a disease,
condition, or disorder, sufficient to cure or at least partially
arrest, or relieve to some extent one or more of the symptoms of the disease, disorder, or condition being treated. The
effectiveness of such compositions depend upon conditions
including, but not limited to, the severity and course of the
disease, disorder, or condition, previous therapy, the
patient's health status and response to the drugs, and the
judgment of the treating physician. By way of example only,
therapeutically effective amounts may be determined by
routine experimentation, including but not limited to a dose
escalation clinical trial.
The specific therapeutically effective dose level for any
particular patient will depend upon a variety of factors
including the disorder being treated and the severity of the
disorder; the specific composition employed; the age, body
weight, general health, sex and diet of the patient; the time
of administration; the route of administration; the rate of
excretion of the specific compound employed; the duration
of the treatment; drugs used in combination or coincidental
with the specific compound employed and like factors well
known in the medical arts. For example, it is well within the
skill of the art to start doses of a compound at levels lower
than those required to achieve the desired therapeutic effect
and to gradually increase the dosage until the desired effect
is achieved. If desired, the effective daily dose can be
divided into multiple doses for purposes of administration.
Consequently, single dose compositions can contain such
amounts or submultiples thereof to make up the daily dose.
The dosage can be adjusted by the individual physician in
the event of any contraindications. Dosage can vary, and can
be administered in one or more dose administrations daily,
for one or several days. Guidance can be found in the
literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a "prophylactically effective
amount"; that is, an amount effective for prevention of a
disease or condition.
Suitable methods for administering to a subject an effective amount of the composition in accordance with the
methods of the present disclosure include but are not limited
to systemic administration, parenteral administration (including intravascular, intramuscular, intraarterial administration), oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical
implantation, transdermal delivery, local injection, and
hyper-velocity injection/bombardment. Where applicable,
continuous infusion can enhance drug accumulation at a
target site (see, e.g., U.S. Pat. No. 6,180,082).
As used herein, the term "subject" refers to a target of
administration of the pharmaceutical composition. The subject of the herein disclosed methods can be a vertebrate, such
as a mammal, a fish, a bird, a reptile, or an amphibian. Thus,
the subject of the herein disclosed methods can be a human
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or non-human. Thus, veterinary therapeutic uses are provided in accordance with the presently disclosed subject
matter. As such, the presently disclosed subject matter
provides for administration to mammals such as humans and
non-human primates, as well as those mammals of importance due to being endangered, such as Siberian tigers; of
economic importance, such as animals raised on farms for
consumption by humans; and/or animals of social importance to humans, such as animals kept as pets or in zoos.
Examples of such animals include but are not limited to:
carnivores such as cats and dogs; swine, including pigs,
hogs, and wild boars; ruminants and/or ungulates such as
cattle, oxen, sheep, giraffes, deer, goats, bison, and camels;
rabbits, guinea pigs, and rodents. Also provided is the
treatment of birds, including the treatment of those kinds of
birds that are endangered and/or kept in zoos, as well as
fowl, and more particularly domesticated fowl, i.e., poultry,
such as turkeys, chickens, ducks, geese, guinea fowl, and the
like, as they are also of economic importance to humans.
Thus, also provided is the treatment of livestock, including,
but not limited to, domesticated swine, ruminants, ungulates, horses (including race horses), poultry, and the like.
The term does not denote a particular age or sex.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.
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Atomic Force Microscopy (AFM) Imaging
Atomic force microscopy (AFM) was used to study the
shape and size of 3 WJ-pRNA nanoparticles harboring three
monomeric pRNA [27]. AFM images were obtained by
5 imaging the nanoparticles using specially modified mica
surfaces (APS mica) [37] with a Veeco MultiMode AFM
NanoScope IV system (Veeco/Digital Instruments, Santa
Barbara, Calif.), operating in tapping mode, according to the
method previously reported [27].
Temperature Gradient Gel Electrophoresis (TGGE)
10
The thermodynamic stability of 2'F U/C modified RNA
3WJ nanoparticles was studied using the TGGE system
(Biometra GmbH, Germany). The 2'F U/C modified RNA
oligonucleotides used in this study for constructing the RNA
15 3WJ nanoparticles were ordered from TriLink Bio Technologies (San Diego, Calif.). The 3WJb strand was 5'-end y-32P
ATP (Perkin-Elmer, MA) labeled prior assembly. Assembly
of RNA 3WJ nanoparticle was achieved by mixing 10 uM
total RNA strands in TMS buffer, heating to 80° C. and
20 cooling it down to 4 ° C. over 1 hour. RNA nanoparticles
were subjected to a 15% native PAGE (2.5 uL of RNA per
well) and allowed to run for 10 minutes at ambient temperature at constant 100 V. After RNA entered into the gel
matrix, the gel was transferred into TGGE apparatus and a
25 linear temperature gradient was set up from 36° to 80° C.
perpendicular to electrical current. The gel was ran at 100 V
for 1 h, and then was dried under vacuum and imaged using
a phosphor storage screen with Typhoon FLA 7000 (GE
Healthcare).
30
Confocal Microscopy of HT29 Colon Cancer Cells IncuExample 1
bated with RNA Nanoparticles
Colon cancer HT29 cells were plated on coverslips
Radiation reagents that specifically target tumors are in
(Fisher Scientific) with folate free medium in a 24-well plate
and cultured at 37° C. in humidified air containing 5% CO2
high demand for the treatment of cancer. The field of RNA
nanotechnology can provide new opportunities for targeted 35 overnight. The cells were washed with folate free medium
twice to remove dead cells. The Alexa-647 labeled foalteradiation therapy. We recently found that chemically modified RNA nanoparticles derived from pRNA Three-Way
3WJ and folate free 3WJ 2'F RNA nanoparticles were
Junction (3 WJ) of phi29 DNA-packaging motor are resistant
diluted in folate free medium and incubated with the cells at
to potent I-125 and Cs-131 radiation, which is a required
37° C. for 2 hours. After washing with PBS, the cells were
perquisite for utilizing these RNA nanoparticles as carriers 40 fixed with 4% paraformaldehyde, stained with Alexa Flour®
for targeted radiation therapy. Specifically, RNA nanopar488 Phalloidin (Life technologies Corporation, Carlsbad,
ticles derived from the pRNA 3WJ targeted tumors in vivo
Calif., USA) for actin and ProLong® GoldAntifade Reagent
and they were stable under irradiation of I-125 and Cs-131
with DAPI (Life technologies) for nucleus. The images were
with clinically relevant doses ranging from 1 Gy to 90 Gy
taken on an Olympus FVl000 confocal microscope (Olymover a significantly long time up to 20 days. These studies 45 pus Corporation, Tokyo, Japan).
demonstrated that the RNA nanoparticles could be used as
Flow Cytometry Analysis of Cellular Binding of RNA
carriers for radiation therapy and diagnosis.
Nanoparticles
KB cells were cultured in folate free RPMl-1640 medium
Materials and Methods
Oligonucleotides and Assembly of RNA 3WJ Nanopar(Gibco ), then digested with trypsin and rinsed with folate
50 free medium. 3 nM of Alexa647 labeled 3WJ-Folate and
ticles
3WJ 2'F RNA were incubated with 2xl0 5 KB cells at 37° C.
The RNA oligonucleotides used in this study for constructing the RNA 3WJ nanoparticles were ordered from
for 1 hr. After washing with PBS twice, the cells were
TriLink BioTechnologies (San Diego, Calif.). Assembly of
re-suspended in 200 µL of PBS buffer for flow cytometry
RNA 3WJ nanoparticles was performed by mixing equal
analysis. Fluorescence intensity was determined with a
molar concentrations of corresponding strands (3WJa: 55 FACS Calibur flow cytometer (BD Biosciences) by counting
UUGCCAUGUGUAUGUGGG (SEQ ID NO: 1); 3WJb:
20 000 events each sample.
CCCACAUACUUUGUUGAUCC (SEQ ID NO: 2) and
Cytotoxicity Assay
3WJc: GGAUCAAUCAUGGCAA (SEQ ID NO: 3)) in
The cytotoxicity of RNA nanoparticles were evaluated
TMS(50mMTRISpH=8.0, l00mMNaCl, 10mMMgC12 )
with an MTT assay kit (Promega, Madison, Wis.) following
buffer. The 3WJ formations were confirmed on a 12% native 60 manufacture' s instruction. Briefly, HT29 cells were plated in
a 96-well plate and cultured at 37° C. in humidified air
PAGE (polyacrylamide gel electrophoresis) with running
buffer (89 mM Tris, 200 mM Borate acid, and 5 mM
containing 5% CO2 overnight. The folate-3WJ 2'F RNA
MgC1 2 ), according to published procedure [27]. Gels were
nanoparticles were suspended in fresh McCoy's SA with
10% FBS medium at the indicated concentrations and added
stained with ethidium bromide (EB) or SYBR Green II and
imaged by Typhoon FLA 7000 (GE Healthcare). The 65 to the cells for incubation at 37° C. for 24 hrs. Then, 15ul
assembled RNA 3WJ nanoparticles were stored in -20° C.
of dye solution was added to each well and incubated at 37°
freezer prior to further characterization.
C. for 4 hrs; 100ul of solubilization/stop solution was added
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to each well and incubated at room temperature for 2 hrs for
color development. The absorbance at 570 nm was recorded
using a microplate reader (Synergy 4, Bio Tek Instruments,
Inc, USA). The cell viability was calculated relative to the
absorbance of cells only control (viability of cells only
control=100%).
Animal Trial: In Vivo Cancer Targeting of RNA 3WJ
Nanoparticles
In order to evaluate the cancer targeting property of RNA
3WJ nanoparticles, an animal trial was conducted. All
experiments involving animals are approved by the University of Kentucky Institutional Animal Care and Use Committee (IACUC). Male athymic nude nu/nu (6-8 week old)
mice were obtained from Taconic (Hudson, N.Y.) and
housed in clean, pathogen-free rooms in an environment
with controlled temperature (27° C.), humidity, and a 12
hour light/dark cycle. The mice were fed standard chow and
tap water ad libitum and allowed to acclimate for one week.
HT29 colon cancer tumor cells were injected subcutaneously (5xl0 6 cells in 100 ul lx phosphate buffered saline
(PBS)). RNAnanoparticles were administered intravenously
3 weeks after tumor cells injection. The folate and Alexa64 7
labeled 2'F U/C modified RNA oligo strands for assembling
the RNA 3WJ nanoparticles were custom ordered from
TriLink BioTechnologies, Inc (San Diego, Calif.). Mice
were fed a folate-free diet (Harlan Laboratories; Indianapolis, Ind.) for a total of 2 weeks before the folate-pRNA 3WJ
nanoparticles were injected. For intravenous injection mice
were anesthetized using isoflurane gas (2% in oxygen at 0.6
Umin flow rate) and injected with 100 µg (4 mg/kg) of 2'F
U/C modified folate-Alexa647-labeled pRNA 3WJ nanoparticles in 300 µl of PBS. Whole-body imaging (Alexa Fluor
647, Ex=640 nm, Em=680 nm;) was carried out on IVIS
Spectrum station (Caliper Life Sciences; Hopkinton, Mass.)
15 min, 1 hour, 2 hour and 3 hour post injection. Composite
images obtained were comprised of black and white digital
photos with an overlay of images reflecting fluorescent
activity. The density map, measured as photons/second/cm2/
steradian (p/s/cm2/sr), was created using the Living Image
3.1 (Caliper Life Sciences; Hopkinton, Mass.) software and
represented as a color gradient centered at the maximal spot.
CO2 asphyxiation was performed by 3 hand 15 minute post
injection. Following CO2 asphyxiation, the tumors of the
mice were dissected.
Confocal Microscopy of Tissue Samples
For in vivo samples, collected tissues were fixed in 4%
paraformaldehyde (Polysciences; 18814) with 10% sucrose
(Sigma-Aldrich; St. Louis, Mo.) for 12 h at 4° C. and
embedded into Tissue-Tek® O.C.T. compound on dry ice
(Tissue-Tek; Andwin Scientific, Schaumburg, Ill.) for frozen
sectioning (10 µm section thickness). Sectioned tissues were
dried overnight in the dark, washed in room temperature
PBS, stained and mounted by ProLong® Gold Antifade
Reagent with DAPI (Life Technologies Corporation, Carlsbad, Calif.) overnight. The Olympus FVl000 confocal
microscope (Olympus Corporation, Tokyo, Japan) was used
to obtain the images.
Urea Stability Assay
Urea is a denaturing agent that is widely used in biochemistry to denature RNAs or proteins. Urea stability
assays were performed to assay the stability of RNA 3WJ
nanoparticles in the presence of urea. Urea stability was
tested by mixing assembled RNA 3WJ nanoparticles with
different concentrations of urea (2 M, 4 M, 6 M and 8 M).
The samples were assayed on a 12% native PAGE, stained
with EB, and imaged by Typhoon FLA 7000 (GE Healthcare).
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Fetal Bovine Serum (FBS) Degradation Assay
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Stability of nanoparticles in the body is critical for its in
vivo application, as many enzymes could degrade nanoparticles rapidly and hinder their application. In the blood, the
instability of RNA is mainly the result of enzymatic degradation by ribonucleases (RNases). RNases can be divided
into two major categories: endoribonucleases and exoribonucleases. Endoribonucleases cleave phosphodiester bonds
within the RNA backbone, while exoribonucleases cleave
phosphodiester bonds at either the 5' end or the 3' end of an
RNA chain. RNA is indeed very sensitive to degradation by
RNases, which confers a very short half-life and thus, a poor
pharmacokinetic profile for most RNA molecules. This
limits the in vivo usage of RNA molecules as therapeutics.
However, chemical modifications of RNA can overcome this
shortcoming. For example, the substitution of the 2'
hydroxyl group with a 2' fluorine (2'F) atom dramatically
increases the stability of RNA in vivo by preventing degradation by RNases [48-51]. To test the stability of RNA
3WJ nanoparticles with FBS treatment, assembled RNA
3WJ nanoparticles were incubated with 10% FBS in 1640
cell culture medium in a 37° C. water bath for different time
up to 36 hr. Samples were then assayed on a 12% native
PAGE, stained with EB, and imaged by Typhoon FLA 7000
(GE Healthcare). ImageJ software was used to integrate the
intensities of the assembled RNA 3WJ nanoparticles in the
gel. Integration areas for each time point were compared to
the integration area for the 0 min time point to construct a
serum degradation comparison between the RNA and 2'F
RNA nanoparticles. Origin 8.6 software were used to generate the plots.
Irradiation of RNA 3WJ Nanoparticles with I-125 and
Cs-131
Two brachytherapy sources were used in this study. I-125
is an isotope that is commonly used to treat prostate cancer
and tumors in various sites. It decays into Te-125 with
electron capture emitting photons with a broad spectrum
whose mean energy is 28 KeV; the half-life is 59.4 days.
I-125 brachytherapy sources used in this study for prostate
implants were produced by IsoAid (Port Richey, Fla.) as a
cylindrical shape with a physical length of 4.5 mm and outer
diameter of 0.8 mm; the I-125 material was coated onto a
silver rod encapsulated with a thin Titanium shielding [38].
Isotope Cs-131 is relatively new to brachytherapy, but has
already been used for the treatment of various types of
cancer such as prostate, breast, and eye, and recent gynecological malignancies [39-44]. It is similar to I-125 in many
aspects. It also decays in electron capture and emits photons
with a mean energy of 30 KeV, but the half-life of Cs-131
is only 9.7 days [45]. The Cs-131 source was provided by
IsoRay Medical, Inc., Richland, Wash. as a small cylinder
4.5 mm in length and 0.8 mm in diameter.
I-125 or Cs-131 radioactive sources were immersed in the
sample liquid (1 cc) contained in a small vial. The irradiation
of the 2'F U/C modified RNA samples was performed for
different time periods and doses. The purpose was to distinguish the effects of radiation on DNA and RNA structures.
Un-irradiated samples were maintained in the same buffer
and temperature and used as control. After irradiation, the
integrity of the RNA 3 WJ nanoparticles and plasmid control
were assayed by 12% native PAGE with TBM running
buffer or 0.7% agarose gel with TAE running buffer, respectively.
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Results
RNA 3WJ Nanoparticles Form by One-Pot Self-Assembly
RNA 3WJ consists of three fragments: 3WJa, 3WJ6 , and
3WJc RNA nanoparticles were formed by mixing three
pieces of chemically synthesized oligos, 3WJa, 3WJ6 , and
3WJc at 1:1:1 molar ratio (FIG. 1). The three pieces were
assembled into nanoparticles very efficiently by simple
mixing (FIG. lC, lane 7), indicating the thermodynamically
stable properties of the pRNA 3WJ. Notably, with the 1:1: 1
ratio of 3WJa, 3WJb, and 3WJc, almost more than 90% or
close to 100% of the three RNA fragments assembled
efficiently into the 3WJ complex. This feature of efficient
self-assembly [27] suggests that pRNA 3WJ nanoparticles
can be fabricated very simply and easily, which is advantageous for therapeutics development and clinical translation.
AFM imaging also confirmed the formation of 3WJ-pRNA
nanoparticles harboring three monomeric pRNA and
revealed the triangular branched structure of the nanoparticle with the size of 10-15 nm (FIG. 18).
Chemically Modified RNA 3WJ Nanoparticles are
Chemically and Thermodynamically Stable
In addition, we measured thermodynamic stability of the
RNA 3WJ nanoparticles by temperature gradient electrophoresis gel (TGGE) (FIG. lD). This technique allows the
determination of melting temperatures of nucleic acids by
means of decreasing fraction of a nanoparticle with increasing temperature on PAGE [46,47] (FIG. lD). The 2'F
modified 3WJ nanoparticles remained stable at temperatures
as high as 66.8±2° C., which is above the temperature of
normal human body.
RNA 3 WJ nanoparticles were mixed with 2 M, 4 M, 6 M,
and 8 M urea and loaded into TBM gel (FIG. 3A). In the
presence of 8 M urea, assembled RNA 3WJ nanoparticles
still showed little dissociation, which is in agreement with
previously published results [27].
The stability of RNA 3WJ nanoparticles was tested with
up to 36 hr serum treatment (FIG. 3B). Previously published
reports by Pieken et al. [48], Kawasaki et al. [49], Sabahi A
et al. [50] and Liu et al. [51] have demonstrated that
2'F-modified RNA has increased resistance to ribonuclease
as well as enhanced thermodynamic stability. Our results
showed the similar results for the RNA 3WJ nanoparticles.
Specifically, unmodified RNA 3WJ nanoparticles were
degraded in serum which was revealed by the disappearance
of the non-modified RNA 3WJ nanoparticles after serum
treatment, indicating the majority of the unmodified RNAs
were degraded. However, 2'F-modified RNA 3WJ nanoparticles were resistant to serum-induced degradation. In contrast to unmodified RNA nanoparticles, more than 90% of
2'F-modified RNA 3WJ nanoparticles remained intact after
36 hours serum treatment, which is in agreement with
published reports [27].
Folate-Conjugated RNA Nanoparticles Bind to Cancer
Cells Specifically In Vitro
In one embodiment, the 2'F modified 3WJ RNA nanoparticles conjugated with folate were tested for specific
binding and entry to colon cancer HT29 cells by confocal
microscopy. In the folate-conjugated 3WJ RNA nanoparticles, 3WJb strand was labelled with folate and 3WJc strand
was labeled withAlexa647. 3WJ RNAnanoparticles without
folate were used as a negative control. Confocal imaging
indicated strong binding and entry of the folate-conjugated
3WJ nanoparticles to colon cancer HT29 cells, as demonstrated by co localization of nucleus (blue), actin (green) and
Alexa647-labeled RNA nanoparticles (red) signals. (FIG.
2A). Flow cytometry analysis indicated that folate labeled

3 WJ 2'F RNA nanoparticles can also bind to folate receptor
over-expressed KB cells (FIG. 2B).
RNA 3WJ Nanoparticles Holds Low Cytotoxicity
Revealed in Cell Assay
The cytotoxicity offolate-3WJ 2'F RNAnanoparticles on
colon cancer HT29 cells was evaluated with a standard
colorimetric MTT assay that assesses the cell proliferation.
We found that folate 3WJ 2'F RNA nanoparticles did not
induce measurable cell viability loss on colon cancer HT29
cells even at a high concentration of 0.4 µM (FIG. 2C),
indicating the RNA nanoparticles are biocompatible and not
toxic.
RNA 3WJ Nanoparticles Targeting Xenograft Cancer by
Systemic Injection
Systemic injection ofRNA3WJ nanoparticles was used to
confirm the chemical and thermodynamical stability and
cancer targeting of these nanoparticles. Moreover, as a
preliminary study to evaluate the feasibility of RNA nanoparticles to carry radioisotopes for cancer targeting in vivo,
we used fluorescent dye instead of a radioisotope in a pilot
experiment. RNA nanoparticles was constructed with one
RNA fragment carrying folate as a cancer-targeting ligand
and another RNA fragment carrying the Alexa647 fluorescent probe instead of a radioisotope. The 3WJ RNA nanoparticles were systemically injected into mice via tail vein.
Whole body imaging of treated mice revealed a fluorescence
signal located specifically at the cancer xenograft, which
expressed the folate-receptor. Fluorescent signal was not
detected in healthy tissue or normal organs in the mice body
(FIG. 2D), indicating that the particles did not accumulate or
become trapped in liver, lungs, or other organds after systemic delivery. Further confocal microscope analysis (FIG.
2E) also confirmed that the Alexa647 labeled RNA nanoparticles could enter into the tumor and bind to cancer cells.
RNA 3WJ Nanoparticles are Stable Under Irradiation
with I-125 and Cs-131
The stability of 2'-F modified RNA 3WJ nanoparticles
under irradiation with clinically relevant doses was crucial
for the development of targeted radiation therapy. The
stability tests were performed with I-125 and Cs-131 irradiation. DNA plasmids were included as control. The plasmid DNA we used was in the circular form. Cleavage of the
circular plasmid at a random site will result in a linear DNA
that migrates to different location in the gel. Multiple
cleavage of the DNA will result in random sizes that form a
smear in the gel and many individual bands with low
concentration were not visible since each DNA will have
several thousand random cleavage sites. The test with I-125
was first performed for a low dose of 1 Gy to both RNA and
DNA samples, but no change was observed. When the dose
was increased to 30 Gy, a typical therapeutic dose, RNA
3WJ nanoparticles still remained unchanged (FIG. 3C)
while DNA smear was formed as shown in FIG. 3D, which
provided evidence of the cleavage of the plasmid DNA by
radiation. The upper band and lower bands in lane 1 represent linear and supercoiled plasmid DNA, respectively.
These results are summarized in Table 1.
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Results ofl-125 irradiation.
60

Test

Dose (Gy)

Sk(U)

Time (day)

1.4
2
Y

30

1.7

18

RNA change DNA change
N
N

N

y

= Yes, N = No.
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Four tests were also conducted with Cs-131 for 7 Gy, 20
Gy, 30 Gy, and 90 Gy, and the irradiation lasted up to 20

US 10,828,381 B2
35

36

days (longer than 2 half-life of 9.7 days). Both DNA and
RNA structures were intact for 7 Gy, but DNA was broken
while RNA 3WJ nanoparticles remained intact for 20 Gy or
higher. The results are summarized in Table 2, and the result
for 30 Gy is shown in FIG. 3D.

nanoparticles are feasible to carry radioisotope to kill cancer
cells while remaining intact. The stability of the RNA
nanoparticles under irradiation over a long time is important
since the chemical conjugation of radioactive isotopes to
RNA might be a time-consuming process depending on the
rate and efficiency of the conjugation reaction. In the future
experiments, we will also study the stability of RNA nanoparticles inside tumor tissues and try to develop the method
to control the degradation of RNA nanoparticles as well as
the release of radioisotope inside the tumor. In addition,
I-125 and Cs-131 are gamma emitters and presence of
gamma emission is helpful in imaging and studying the
biodistribution of the radiopharmaceutical for estimation of
patient-specific dose distribution [57]. This is an advantage
that gamma emitters have over the pure beta emitters like
Y-90. In the absence of gamma emission, surrogate isotopes
like In-111 have to be used for internal dosimetry for pure
alpha or beta emitters such as Y-90. Compared to I-131 that
also emits photons, I-125 and Cs-131 have much lower
energies and easy for radiation protection. Although image
quality for I-125 or Cs-131 will be affected by the low
energies of photons, good quality I-125 image have been
obtained using Gamma camera [58, 59]. Therefore, RNA
nanoparticles carrying I-125 or Cs-131 have the potential to
be used for accurate targeted radiation therapy. As disclosed
herein, in some embodiments, beta emitters include but not
limited to Strontium-90, Tritium, Carbon-14, Phosphorus32, Nickel-63. In some embodiments, gamma-emitting isotopes include but not limited to Caesium-137, Iodine-131,
Lanthanum-140, cobalt-60, iridium-192.
It should be noted, however, that the sealed I-125 and
Cs-131 sources used in this study were not carried by RNA
nanoparticles. To be carried by RNAnanoparticles, unsealed
I-125 or Cs-131 should be used to label RNAnanoparticles.
The I-125 or Cs-131 labeled RNA nanoparticles will be
injected into the patient body to target the tumor, and the
radiation from I-125 or Cs-131 can thus kill the cancer cells
guided by the nanoparticles. The I-125/Cs-131 labeled RNA
particles will stay inside the tumor cells to deposit almost all
the dose produced by I-125/Cs-131. Considering that the
blood circulation time for humans is about one minute
compared to the half-life of I-125/Cs-131 of about 60
days/IO days, the dose lost during circulation is negligible.
Detailed discussion of I-125/Cs-131 labeled RNA particles
will be addressed in our future study. Based on the biodistribution study of pRNA nanoparticles published by Abdelmawla et al. [28], we expected that 3WJ nanoparticles
labelled with radioisotope will also have favorable biodistribution profile with similar tumor-targeting efficiency as
the previously reported pRNA nanoparticles. In the future
experiments, we will radioactively label 3WJ RNA nanoparticles and use the radioactive signal to quantify the doses
delivered in individual organs and tumor. We will also
compare the delivered dose to that provided by brachytherapy implanted sources.
Conclusions
Chemically modified RNA nanoparticles derived from
pRNA three-way junction (3WJ) ofphi29 DNA-packaging
were resistant to the radiation of I-125 or Cs-131 and
remained stable under irradiation with therapeutic doses
over a significantly long time up to 20 days. Therefore, RNA
3WJ nanoparticles have the potential to carry I-125 or
Cs-131 for targeted radiation therapy.
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TABLE 2
Results of Cs-131 irradiation.
Test

Dose (Gy)

2
3

20
30
90

7

4

Sk (U)
0.98
1.47
4.03
8.57

Time (day)
7

20
7

11

RNA change DNA change
N
N
N
N

10

N
y
y
y
15

Y

= Yes, N = No.

The results showed that RNA 3WJ nanoparticles were
stable under irradiation of I-125 and Cs-131 with doses
ranging from 1 Gy to 90 Gy. However, the DNA plasmids
were damaged with a dose of 20 Gy or higher, the therapeutic doses prescribed for cancer treatment, while the RNA
3WJ nanoparticles remained intact. This result has indicated
that RNA 3WJ nanoparticles may be able to carry therapeutic doses of I-125 and Cs-131 for cancer treatment.
Discussion
RNA nanotechnology is an field with increasing popularity among the scientific community [13, 21, 52-56]. RNA
3WJ-based nanoparticles have been successfully fabricated
(FIG.1) and share the advantages ofa targeted drug delivery
system of specific delivery and longer retention time, which
reduce the dosage required and the side effects. The specific
delivery can be achieved through EPR (enhanced permeability and retention) effect or active targeting through
conjugation with ligands such as aptamer, folate, and RGD.
Systemic injection of thermodynamically and chemically
stable RNA nanoparticles into mice revealed that RNA
nanoparticles strongly and specifically bound to cancers
without accumulating in liver, lung, or any other vital organs
or tissues (FIGS. 2D and 2E).
The high stability of RNA 3WJ nanoparticles in the
presence of high concentration of denaturing agents (FIG.
3A) is a remarkable advantage for in vivo applications,
including radiation therapy, because remaining intact in vivo
and being resistant to various denaturing factors will be
crucial for fulfilling the nanoparticle's designated function
after injection into the body. Moreover, the determined
melting temperature of the 3WJ RNA nanoparticles (FIG.
lD) is approximately two times higher than the normal
human body temperature (37° C.), which also indicates that
this physical property of the RNA 3WJ nanoparticles is
favorable for in vivo applications including radiation
therapy, because these RNA nanoparticles should not disassociate within the normal human body temperature range.
Furthermore, the property of resistance to serum-induced
degradation (FIG. 3B) suggests that these 2'F modified RNA
nanoparticles will also stay intact within the human body,
and, again, should be favorable as a targeted delivery system
for in vivo cancer therapy.
The principle of radiation therapy is to use radiation to
break DNA helical structures in the cancer cells. However,
RNA has similar structures. To be able to carry radioisotopes, RNA structures should keep intact with the radiation.
The study has shown that, unlike DNA, RNA nanoparticles
were resistant to the radiation of I-125 or Cs-131 and
remained stable under irradiation with therapeutic doses
(FIGS. 3C and 3D, Table I and II). This indicates that RNA
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This study will utilize pRNA-3WJ as a platform for
constructing RNA-3WJ-Beacons and RNA Dendrimers as
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multifunctional systems harboring multimodal imaging
agents, cancer targeting ligands, and therapeutic siRNA/
miRNA, all in one nanoconstruct that will allow the delivery
of therapeutics to be visualized at various spatial and temporal resolutions in vivo. Example 2 focuses on the construction of multifunctional pRNA-3WJ nanoparticles harboring (1) imaging modules: NIR fluorophores, such as
Alexa 647 and IRdye 800 for in vivo fluorescence imaging;
Radionuclides, such as 177 Lu, 111 In or 64 Cu for PET/SPECT
imaging; and Contrast agents, such as gadolinium (Gd3 +) for
MRI; (2) targeting modules: such as RNA aptamer or
chemical ligand for binding to cancer specific cell surface
receptors resulting in internalization of RNA nanoparticles
into cancer cells; and (3) therapeutic modules: siRNAs or
anti-miRNAs to down-regulate oncogenic genes.
Construction of Multifunctional RNA Nanoparticles Harboring Multimodal Imaging Agents, TargetingAptamers and
Therapeutic Modules Using pRNA-3WJ Platform
Multifunctional RNA nanoparticles will be constructed
using the pRNA-3WJ motif as a scaffold to harbor: (1)
Imaging modules: NIR fluorophores for in vivo fluorescence
imaging; Radionuclides for PET/SPECT imaging; and gadolinium contrast agents for MRI; (2) Targeting modules: RNA
aptamers or chemical ligands for binding to cancer specific
cell surface receptors resulting in internalization of RNA
nanoparticles into cancer cells; and (3) Therapeutic modules: siRNAs and anti-miRNAs to down-regulate oncogenic
genes.
1.1 Conjugation of Imaging Modules to RNA Constructs
1.1.1 Nir Fluorophores:
For in vivo imaging, NIR dyes are particularly attractive
since they can penetrate deep into tissues and more importantly, auto-fluorescence from tissues is greatly reduced.
without being bound by theory, a robust RNA nanotechnology will be developed utilizing the pRNA-3WJ motif for
monitoring the in vivo delivery of therapeutics non-invasively by NIRF and PET/SPECT imaging (FIG. 12). The
RNA-3WJ-Beacon contains a 'reporter' fluorophore darkened by a quencher in close proximity and will only elicit a
fluorescence signal upon cleavage of the incorporated
siRNA/anti-miRNA by Dicer in the cell (see Section 2.1,
described herein in Example 3). The RNA-3WJ-Beacon also
contains a 'reference' probe (either NIR dye or radiolabel),
which remains active at all times and allows tracking of the
entire RNA-3WJ-Beacon construct in the cell (FIG. 12).
The pRNA-3WJ motif utilizes a modular design composed of three individual fragments (FIG. 6F, 12). One of the
fragments (c 3 wJ) will be end-labeled with 'reference' dye
IRdye 800 while another fragment (b 3 wJ) will be end-labeled
with a quencher, Iowa Black for the 'reporter' dye Alexa 647 .
The 'reporter' dye will be end-labeled on therapeutic RNA
fragments (siRNA/miRNA). All these 2'-F modified RNA
fragments will be custom-designed and purchased from IDT,
TriLink or IBA, as described in our publications [G9-11,
which are incorporated by reference in their entitities.] Upon
mixing the chemically synthesized individual strands in
stoichiometric ratio, the RNA fragments will assemble into
an ultrastable 3WJ nanoparticle with high efficiency, as
shown in our publications [G9-ll].
It is important to note that the NIR fluorophores and
quenchers used herein are highly soluble in physiological
buffers, display very low nonspecific binding to cellular
components and have high signal-to-noise ratio [G72]. In
our RNA-Beacon constructs, the fluorescence spectrum of
the 'reference' and 'reporter' dyes are designed such that
there are no potential spectrum overlaps or quenching

through FRET (FIG. 13). As alternatives, other available
quencher/emitter pairs (Table 3) will be investigated.
TABLE 3
5

10

Emitter-quencher pairs for designing RNA
molecular beacons (as alternatives)
Emitter

Quencher

Alexa64 7/Cy5
IRDye 800CW
Cy5.5/Alexa-680

Iowa Black RQ/QSY21
IRDyeQC
BBQ650/BHQ-3

Source: Trilink, IDT, Invitrogen; Li-COR

15

20

25

30

35

40

45

50

55

60

65

1.1.2 Radionuclide:
radiolabel peptides and proteins with various isotopes
(1 77 Lu, 111 In, 64 Cu, 99 mTc, 203Pb, 188 Re, 212 Pb/212 Bi) have
been developed as tumor specific diagnostic and therapeutic
agents [G73-77]. Similar methodologies will be applied to
label RNA constructs used in this study.
Radionuclide Selection:
1 77
Lu, 111 In or 64 Cu (as alternatives) will be used to label
the RNA nanoparticles. High specific activity of these radionuclides are commercially available. Metals are highly toxic
in their free form and thus have to be chelated to minimize
their toxicity. We will use DOTA(l,4,7,10-tetraazacyclododecane-N,N'N'N""-tetraacetic acid) or NOTA (1,4,7-triazacyclononane-N,N' ,N"-1,4, 7-triacetic acid) as chelating
agents for our radionuclides.
Lutetium-177 (t 112=6.71 days, (30.497 MeV, Yavg 175
keV) is an attractive radioisotope for targeted radionuclide
therapy, imaged by SPECT. The DOTAmacrocyclic chelator
can stably coordinate Lutetium-177 at 37° C. to 75° C.
[G73].
Indium-Ill (t 112=2.8 days, EC 100%, y 171 keV, y 245
keV) is a gamma emitter that is routinely used in diagnostic
SPECT nuclear medicine imaging. The DOTA macrocyclic
chelator can stably coordinate 111 In at 3 7° C. to 7 5° C.
[G78].
Copper-64 (t 112=12.7 hrs, 17.4% ~+, 41% EC, 40% ~-,
Eavg 278 keV) is a positron and beta- emitter. The NOTA
macrocyclic chelator can efficiently and stably coordinate
64
Cu from 25° C. to 50° C. 76 .7 9 • The 12.7 hr half-life is
sufficiently long to radiolabel the RNA nanoparticle and
perform biodistribution and imaging studies using PET.
Conjugation of DOTA or NOTA to Amine Modified
Nanoparticles:
One of the fragments (c 3 wJ) of the pRNA-3WJ will be
2'-F modified and end-labeled with amine (NH 2 ) (custom
ordered from Trilink). The c 3 w.rNH 2 RNA will be reacted
with a 50 equivalent excess of DOTA-NHS (for 177Lu,
111
In) or NOTA-SCN (for 64Cu) (Macrocyclics Inc.) (FIG.
14). The DOTA-NHS chelator will conjugated to the RNA
in acetonitrile carbonate buffer (pH 10); NOTA-SCN will be
conjugated to the RNA in sodium bicarbonate buffer (pH 8).
The reactions will be monitored by reverse phase high
performance liquid chromatography (RP-HPLC). Unreacted
DOTA-NHS and NOTA-SCN will be removed from solution using a 7 kDa weight cutoff spin colunm pre-equilibrated in sterile water. The chelator modified nanoparticles
will be lyophilized and stored at -80° C.
Radiolabeling DOTA and NOTA Conjugated RNA:
The chelator conjugated RNA fragment will be radiolabeled in acetate buffer (pH 7) over a concentration range of
0.1-1 nM (20-200 µg) to maximize radiolabeling efficiency
[G80]. DOTA conjugated nanoparticles will be radiolabeled
with 40 MBq of 177LuCl 3 or 111 InCl 3 (>50 mCi/µg; Mall-
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inckrodt Pharmaceuticals) at 60° C. for 40 min [G78].
NOTA conjugated nanoparticles will be radio labeled with 7 5
MBq of 64 CuCl 2 (> 100 mCi/µg; Essential Isotopes Inc.) at
50° C. for 30 min[G76,G80]. Based on the published work
[G76,G78,G79], it is expected to achieve >95% radiolabeling efficiency. Any free radionuclide will be removed using
7 KDa cutoff spin colunms pre-equilibrated with buffered
saline. The radiolabeled strand will then be mixed with the
other 3WJ component strands to assemble the 3WJ nanoparticles (FIGS. 12, 14).
1.1.3 Gadolinium Contrast Agent:
Gadolinium is a common T 1 -weighted MRI contrast
agent. A similar approach using standard NHS chemistry
will be used to couple Gd3 + to RNA using DOTA-NHS
(FIG. 14). GdCl 3 and RNA-DOTA solutions will be mixed
slowly to avoid any precipitation. The solution will be kept
at 75° C. for 1 hr, which will result in -100% incorporation
yield 81 . The chelated RNA strand will be purified by size
exclusion chromatography and then mixed with the other
3WJ component strands to assemble the 3WJ nanoparticles
(FIG. 12,14)) (See Section 3.1 described in Example 4 for
constructing RNA dendrimers with gadolinium).
Without bound by theory, the entire synthesis is kept free
from any metal contamination as DOTA is a strong chelator
for almost all metal cations. If the contamination of metal
cations, such as Zn2 +, Cu2 + and Fe 2 + occurs, it is difficult to
incorporate Gd3 + due to both kinetic and thermodynamic
issues.
1.2 Construct RNA Nanoparticles Harboring Targeting
Ligands
Colon cancer will be used as a model system to evaluate
our multifunctional
RNA constructs in vitro and in our established subcutaneous, orthotopic, and metastatic mouse models (see Section
2.2 described in Example 3).
1.2.1 Folate Ligand:
Many cancer cells, especially from the epithelial origin
overexpress the folate receptor (FR) on the surface elevated
by 1000-fold including colon cancer. Folate receptor density
increases as the stage or grade of the cancer worsens 82 . We
demonstrated that Alexa 647 -FA-pRNA-3WJ constructs efficiently and specifically bound and internalized to FR+ HT29
and KM20 colon cancer cells in vitro (FIG. 15). More
importantly, the RNA constructs specifically and dose-dependently targeted FR+ HT29 colon cancer subcutaneous
xenografts in mice with little accumulation in normal organs
and tissues (FIG. 22). However, targeting the folate receptor
is expected to be successful only in -one-third of all colon
cancers [G83,G84].
1.2.2 2'-F EpCAM RNA Aptamer:
As an alternative to folate, we identified EpCAM (Epithelial cell adhesion molecule [Homo sapiens] GenBank:
AAH14785.1), which is over expressed in primary and
metastatic colon cancers, including stem cells [G85-87]. We
have developed a novel 2'-F 3WJ library system based on
RNA nanotechnology to select 2'-F RNA aptamers using
SELEX[G88-89]. We used this library and successfully
isolated RNA aptamers with an unusually strong binding
affinity for colon cancer EpCAM receptor (FIG. 16).
1.3 Design RNA Constructs Harboring Therapeutic Modules siRNA/Anti-miRNA
For proof-of-concept of our image-guided drug delivery
system, we will incorporate siRNAs targeting luciferase and
evaluate the effects in HT29 or KM20 colon cancer cells
expressing luciferase. To enhance apoptosis of cancer cells,
several groups have tried repeated transfection of siRNA
into cells [G90]. However, repeated administrations or high

doses of siRNA can lead to high cytotoxicity. We have used
the pRNA-X motif as a scaffold to conjugate multiple copies
of luciferase siRNA targeting the same gene locus or different loci in one gene. Gene knock-down effects were
progressively enhanced by increasing the number of siRNA
in the complex [Gl0] (FIG. 17). Furthermore, 1 nM of
pRNA-X nanoparticles with four siRNA modules can
achieve the same silencing effects as 100 nM unformulated
siRNA[Gl0].
Alternative 1: siRNA Targets:
As therapeutic siRNAs, we will induce apoptosis of the
colon cancer cells by inhibiting anti-apoptotic protein survivin using siRNAs, as described in our previous publications[G9,G10,G22]. siRNAs is directed to PI3K (a ubiquitaus lipid kinase) and its downstream effector proteins (Akt
and mTOR) can effectively inhibit CRC cell viability [G9193, herein incorporated by reference in their entirety]. These
siRNAs will be used as alternatives to survivin (UniProtKB/
Swiss-Prat: 0153023).
Alternative 2: Anti-miRNA Targets:
MicroRNAs are small non-coding RNAs (19-25 nt) that
display two classes of function, either as oncogenes or tumor
suppressors[G94-95]. The pRNA-3WJ motif was shown to
be an effective carrier of suppressor miRNA to silence viral
genes by targeting the 3'-UTR of coxsackievirus genome
[G96-97]. Following a similar delivery principle, we will
deliver anti-miRNAs to kill tumors by down-regulating
oncogenic miR-21. MiR-21 regulates biological behavior
through the PI3K/Akt signaling pathway[G98], and downregulating miR-21 will serve as an alternative to our siRNA
strategy. We have constructed a miR-21-luciferase reporter
system and found that pRNA-3WJ-Folate-anti-miR-21
nanoparticles can effectively knockdown miR-21 expression
after incubation (as opposed to transfection) in KB cells
(FIG. 18) (Dan Shu, et al., Systemic Delivery of AntimiRNA for Suppression of Triple Negative Breast Cancer
Utilizing RNA Nanotechnology, ACS NANO, (2015) Vol. 9,
No. 10, pp 9731-9740, hereby incorporated by reference in
its entirety)
Alternative 3: Cytotoxic Drugs:
We have conjugated Paclitaxel (PTX) and Camptothecin
(CPT) to the pRNA-3WJ scaffold using 'click chemistry'
approach and acid-labile bonds (FIG. 19) [US 20130116419;
Kolb, Hartmuth C., M. G. Finn, and K. Barry Sharpless.
"Click chemistry: diverse chemical function from a few
good reactions." Angewandte Chemie International Edition
40.11 (2001): 2004-2021, hereby incorporated by reference
in there entirety]. The RNA-drug-folate complex can effectively induce cell apoptosis in KB cells (FIG. 20).
1.4: Characterize Biochemical and Biophysical Properties
of RNA Nanoparticles
The pRNA-3WJ scaffold harboring different functional
modules retain their folding and independent functionalities
of all incorporated modules 9 •10 . Nevertheless, we will characterize biochemical and biophysical properties of RNA
constructs from Section 1.1-1.3 using well-established
methods: (1) assay RNAnanoparticle folding and assembly
using native gels[G9,G10]; (2) assessment of Tm by quantitative PCR with SYBR Green, temperature gradient gels,
or UV absorbance [G9,G10]; (3) assessment of Kn by
competition assays using radiolabeled/fluorescent labeled
RNA[G9] or SPR; (4) evaluate chemical stability (after 2'-F
modifications) by incubating RNA with RNase or 10% FBS
[G9,G13]; (5) examine resistance to denaturation by 2-8 M
urea in denaturing gels[G9,G10]; (6) structural characterization by AFM imaging[G9-ll]; secondary structure prediction by "m-fold" algorithm [G99]; (7) radiochemical
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stability assays. Briefly, RNA nanoparticles will be initially
examined in PBS (pH 7.4), PBS with 1 mM EDTA and in
serum at 37° C. Samples of the radiolabeled nanoparticle
solution will be removed at various time points over a 24 hr
period and examined by HPLC for evidence of degradation
or transchelation of the radiometal by the competitive metal
chelator EDTA.

on one end and quencher on the other (FIG. 4A). The
fluorophore and the quencher are held in close proximity
resulting in none or low fluorescence signal. Upon hybridization with a perfectly matching complementary RNA
target, the 'reporter' fluorophore and quencher separate and
fluorescence is restored. Our RNA-3WJ-Beacon that contains a 'reporter' fluorophore darkened by a quencher in
close proximity will elicit a fluorescence signal upon cleavage of the incorporated siRNA/miRNA by Dicer in the cell
(FIG. 21). The 'reference' probe (either fluorescent dye or
radiolabel) is present on another strand of the 3WJ complex
and remains active regardless of the conformation of the
RNA nanoparticles.
2.1: In Vitro Characterization of RNA-3WJ-Beacon-(FA
or EpCAM Aptamer)-(siRNA or Anti-miRNA) in Colon
Cancer Cells
2.1.1 Assay Specific Cell Recognition and Entry of Multifunctional RNA-3WJ-Beacon:
The RNA-3 WJ-Beacon carrying FA (or EpCAM aptamer)
will recognize HT29 colon cancer cells specifically and
internalize into the cells through receptor mediated endocytosis. The binding and internalization ofRNA-3WJ-Beacon
will be examined by flow cytometry, and confocal microscopy, with appropriate controls (FIG. 15-16). These assays
are well established in [G9-11,G22,G23]. IRdye 800 has
excitation/emission maxima at 774 mn/789 nm, while
Alexa 647 has excitation/emission maxima at 647 nm/668
nm. 177 Lu, 111 In or 64Cu radionuclides will serve as
alternative 'reference' imaging modules to track the RNA3WJ-Beacons in vivo.
2.1.2 Assay the Gene Silencing Effects of Multifunctional
RNA-3WJ-Beacons:
The RNA-3WJ-Beacon-(FAor EpCAM aptamer)-(siRNA
or anti-miRNA, from Section 1.3 describe in Example 2)
with appropriate scramble controls will be incubated with
colon cancer cells without transfection reagents. Once internalized into the cells and released from the endosome, the
RNAi Induced Silencing Complex (RISC) will bind to the
branch of pRNA-3WJ-Beacon containing the siRNA or
anti-miRNA. If the siRNA/anti-miRNA is processed correctly, it will be released from the 3WJ complex and away
from the quencher, thereby restoring the fluorescence of
'reporter' dye Alexa 647 (FIG. 21). The released siRNA/antimiRNA will trigger knockdown of the target gene in a
dose-dependent manner, which can be tracked in real-time
by monitoring the fluorescence of 'reporter' dye Alexa 647 ,
following published procedures[G 101,G 102,G 105,G 109].
The gene knock-down effects will be validated by functional
assays:
For quantification of luciferase siRNA silencing effects,
we will use HT29-Luciferase expressing cells and image the
cells using IVIS Spectrum system. The luminescence intensity, photon counts per second from each well will be
recorded and plotted. Cell numbers will be quantified by
staining with sulforhodamine B (SRB) assay, as described in
our publications[Gl0,Gll] The relative luciferase activity
will be used to reflect the expression level of firefly
luciferase gene by normalizing the firefly luciferase activity
with SRB readouts. For survivin siRNA, we will use RTPCR and Western blot to determine gene expression at
mRNA and protein levels, respectively, similar to our previous publications [G9,G10,G21-23]. The effects of RNA
nanoparticles on cell growth and apoptosis will be assayed
by routine assays [G9,G10,G21-23], such as WST-1,
TUNEL, in situ caspase activity, DNA fragmentation, and
Annexin V /PI staining.
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Evaluation ofpRNA-3WJ-Beacon Constructs by NIRF and
PET/SPECT Imaging in Colon Cancer Model System
This study focuses on construction of the RNA-3WJBeacon harboring targeting ligands, therapeutic siRNA/antimiRNA, and imaging agents to track the delivery and image
therapeutic responses non-invasively by NIRF and PET/
SPECT in colon cancer mouse models. Detailed histological
assays of tumors will be carried out to verify the in vivo
non-invasive imaging evaluation. RNA-3WJ-Beacons will
be constructed, combining the robust features of the pRNA3WJ delivery platform with the functional components of
molecular beacons and therapeutic siRNA/anti-miRNA as
well as cancer targeting ligands, all in one nanoconstruct
(FIG. 4). Upon target recognition, the RNA-3WJ-Beacon
will generate a 'reporter' imaging signal, which in combination with a 'reference' imaging module will enable us to
track the distribution and transport of RNA therapeutics in
vivo. We have successfully generated orthotopic and metastatic colon cancer mouse models to evaluate the RNA
constructs in vivo.
Significant challenges exist in detecting endogenous gene
expression and silencing in vivo, including probe design, in
vivo delivery, specific targeting, and probe sensitivity.
Molecular beacons to image intracellular RNA expression in
vitro by competitive hybridization method have been
reported[Gl00-108], but they were done in solutions with
defined molecular beacon-target conditions. Although these
studies showed the feasibility of detecting mRNAs and
monitoring the transportation of RNAs in cells, the procedure for delivery of the molecular beacons through microinjection or by liposome delivery has made it difficult to
apply this promising technology into broad research areas or
into a routine clinical procedure. Challenges include: (1)
nuclease degradation of RNA or DNA in vivo; (2) low
signal-to-background ratio; (3) inefficient competitive
hybridization due to steric hindrances; and (4) lack of cell
specificity; and (5) inefficient delivery due to non-specific
accumulation in liver and lungs. To overcome these problems, we have developed an innovative RNA-3WJ-Beacon
platform (FIG. 4B) that incorporates the functionality of
molecular beacons into the robust pRNA-3WJ delivery
system that displays highly efficient cancer targeting capabilities with little accumulation in normal organs such as,
liver, lungs, and kidneys. Upon target recognition, the RNA3WJ-Beacon will generate a 'reporter' imaging signal,
which in combination with 'reference' imaging module will
enable us to track the distribution and transport of the
therapeutics RNA nanoparticles in vitro and in vivo using
our well-established colon cancer model system. Our RNA
constructs are polyanionic in nature and can therefore avoid
nonspecific cell entry across the negatively charged cell
membranes[G67-70]. In addition, they can deliver therapeutics to cells after incubation as opposed to transfection and
microporation, typically used in other systems [G101,G103,
G 105,G 106,G 109,G 11 OJ.
Conventional molecular beacons are stem-loop (hairpin)
structures of oligonucleotide dual-labeled with a fluorophore
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For evaluating miR-21 knockdown, at different time
points, the incubation efficiency will be monitored by fluorescence microscopy or in situ hybridization with miRCURY™ LNA detection probes, following established protocols[G 111]. We will isolate and analyze the total RNA for
miR-21 levels using real-time PCR. The functionality of
miR-21 on its validated targets (ex. PTEN, PDCD4, RECK)
will be assayed by RT-PCR at the mRNA level and Western
blot at the protein level or immunostaining.
Without being bound by theory, the Alex 647 dye that is
attached to the 3'-end of siRNA or anti-miRNA (FIG. 12)
may interfere with the siRNA or miRNA function. This can
be solved by alternating the sense or anti sense strand of the
siRNA. It has been shown that modification of sense or
antisense strands on the siRNA made a difference on the
efficiency of gene silencing[G112]. (2) To account for nonspecific RNA-3WJ-Beacon effects, we will implement published procedures used to determine the extent of nonspecific opening using ratiometric analysis [G113]. Briefly,
the fluorescence ratio (total integrated 'reporter' fluorescence/total integrated 'reference' fluorescence) will be compared with same RNA-3WJ-Beacon samples prior to intracellular delivery. (3) The extent of conventional molecular
beacon binding to target mRNA is highly dependent on the
selection of target sequences and their accessibility[G103].
Our RNA-3WJ-Beacon construct design does not utilize a
hairpin with extended sequences. Once Dicer processes the
siRNA off the 3WJ, the siRNA retains its authentic size and
shape (-21 nt dsRNA) for optimum function.
Alternative Approaches:
(1) In one embodiment, a disulfide linkage between the
siRNA strand and 3WJ core complex will be incorporated.
In presence of a reductive environment in cytoplasm, the
disulfide bond will cleave and trigger activation of the
siRNA and conjugated 'reporter' fluorescence[G104]. (2)
We will employ a photo-decaging strategy using photocleavable linkers, whereby the molecular activity of the
molecular beacon is masked by a photo-responsive caging
group and then recovered by specific light irradiation at a
designated time and location[G114]. In another embodiments, Acid-labile linkers will be used between the siRNA
strand and 3WJ core complex.
2.1.3 Determine the Toxicity Profiles of RNA-3WJ-Beacon Harboring FA (or EpCAM Aptamer), siRNA, (or AntimiRNA) In Vitro:
An issue concern regarding the evaluation of RNA interference is the activation of innate immune responses[G 115117]. We have shown that our pRNA nanoparticles display
favorable pharmacological profiles[G12]. We will use RTPCR analysis, ELISA, and flow cytometry to scout for the
activation of protein kinase R (PKR), toll-like receptor
(TLR) and interferon (INF) pathways in human peripheral
blood mononuclear cells (PBMC)[G12,G118] (FIG. 25).
Cell proliferation (MTT) and apoptosis assays (TUNEL)
will also be performed to assay for cytotoxic effects.
2.2 Validation of Our Multivalent RNA Nanoparticles In
Vivo Using Mouse Models
2.2.1 Subcutaneous Xenograft Model:
Subcutaneous xenograft are good model systems since
they mimic the tumor-extracellular matrix interactions,
inflammation and angiogenesis. We will establish subcutaneous xenografts first by injecting lxl0 6 HT29 tumor cells
directly into the flank and then intravenously inject the
multifunctional RNA constructs. Preliminary data demonstrated that Alexa 647 labeled pRNA-3WJ-Folate constructs
can efficiently target subcutaneous HT29 colon cancer xenografts in mice after systemic injection without accumulating

in normal organs and tissues (FIG. 22). The experimental
designs will include: (1) pRNA-3WJ-Beacon-(FA or
EpCAM aptamer)-(siRNA/anti-miRNA); (2) pRNA-3WJBeacon-(w/o targeting ligands); and (3) pRNA-3WJ-Beacon-(FA or EpCAM aptamer)-(scrambled siRNA/antimiRNA). The frequency of dosing required to achieve tumor
growth inhibition will be determined empirically and will be
monitored over time by whole body NIRF and PET/SPECT
imaging before sacrificing the mice.
Based on previous radionuclide experiences, we will
inject -0.5-1.5 mCi of radiolabeled (1 77 Lu, 111 In or 65 Cu)
RNA-3WJ-Beacon into the tail vein of each mouse[G73,
G74,G76,G119,G120]. Imaging time points and duration of
acquisitions will be dependent on radionuclide half-life and
biodistribution data. Whole body small animal SPECT and
PET images will be obtained on a Siemens INVEON multimodality SPECT/CT system combined with a docking
Siemens INVEON PET system (FIG. 23). Anatomical imaging and X-ray computed tomography (CT) will be performed immediately prior to the PET study.
Organ and tumor imaging, full necropsy, and histological
profiles will be conducted to evaluate tumor regression,
tumor growth delay, survival time extension, and tumor-free
cures. Detailed target gene expression profiles for siRNA
and anti-miRNA mediated therapies will be determined on
both mRNA and protein levels (see Section 2.1.2).
2.2.2 Orthotopic Model:
Orthotopic models more closely mimic the microenvironment of the tumor, since cancer cells grow in their natural
location and therefore replicate colon cancer with high
fidelity. We will generate several orthotopic xenografts in
nude mice by injecting lxl0 6 HT29 cells expressing
luciferase directly into the cecum of nude mice after surgical
procedures (laparotomy for exposure of the cecum). The
tumor growth will be monitored by bioluminescence imaging (FIG. 24A). The promising RNA constructs from subcutaneous xenograft assays will then systemically injected in
mice monitored over time by whole body fluorescence and
PET/SPECT imaging before sacrificing the mice, as
described in Section 2.2.1.
Alternative Approach:
Xenografts derived directly from patients have better
retention of the morphological features, such as human
stroma and are more heterogeneous than tumors derived
from established cell lines, and, therefore, represent important in vivo models. We will generate orthotopic xenografts
using these heterogeneous patient-derived tumor cells and
evaluate the therapeutic effects of our RNA nanoparticles.
2.2.3 Metastasis Model:
We will test whether our new RNA constructs can be used
to track down colon cancer metastasis. Liver metastasis will
be established by injecting HT29 cells expressing luciferase
directly into the spleen or the wall of the cecum and
monitored by bioluminescence imaging (FIG. 21A). Preliminary data demonstrated that after systemic injection in
mice, Alexa 647 -labeled pRNA-3WJ nanoparticles efficiently
targeted HT29 liver metastatic cells, but not the normal liver
parenchyma cells (FIG. 24). The RNA-3WJ-Beacon will be
injected intravenously and monitored over time by whole
body NIRF and PET/SPECT imaging before sacrificing the
mice, as described in Section 2.2.1., described here in
Example 3.
Without being bound by theory, targeting a single pathway, such as anti-apoptotic machinery may not result in
significant tumor regression in vivo. We will therefore
evaluate cocktail treatment strategies using multifunctional
RNA constructs harboring siRNA/anti-miRNA. (2) For in
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vivo delivery of RNA therapeutics, an important consideration is endosome escape. We are currently developing a
'click chemistry' approach to incorporate endosome disrupting agents (for proton sponge effect) to our 3WJ scaffold. (3)
Lack of an immune system in SCID mice can profoundly
affect tumor development and progression. We will use
IL2rg_1_ NOG (NOD-SCID IL2rg_1_) mice, which can be
readily humanized using hemopoietic stem cells. After
establishing orthotopic xenografts in mice, we will inject
human PBMCs, and bone marrow to develop functional
blood and immune systems[G121]. We can then systemically inject the RNA constructs and assay the therapeutic
effects.
2.2.4 Assessment of Biodistribution and Pharmacokinetic
Profiles in Mice:
Our pRNA scaffold display favorable pharmacological
profiles: 10-fold (5-10 hrs) enhancement in half-life compared to regular siRNA counterparts (0.25-0.75 hrs); CL of
<0.13 L/kg/hour; V d of 1.2 L/kg; non-induction of interferon-I or cytokine production in mice. Repeated intravenous administrations in mice, up to 30 mg/kg, did not result
in any toxicity (FIG. 25) [G12]. Previous studies were done
using Alexa 647 labeled RNA nanoparticles, and due to
quenching by the blood, the overall uptake by tumors and
organs can be underestimated. We will add an additional
radiolabel component (1 77 Lu, 111 In or 64 Cu) to quantitatively assess the biodistribution (organ and tumor accumulation), PK/PD, and toxicity profiles of RNA constructs,
following our previous publications [G12,G76,G77]. The
percent injected dose per gram(% ID/g) and percent injected
dose (% ID) will be calculated for each tissue.

lation time, slowed down molecular rotation which resulted
in a short relaxation time, and increase in relaxivity, and this
in tum improved resolution and sensitivity.
Without being bound by theory, if the negatively charged
RNA polymer can replace PAMAM and PPI to build dendrimers, it will avoid the interaction with negatively charged
cell membrane and will not trigger non-specific cell entry
and associated toxicity [G134,G135]. The body treats RNA
as a material of its own and will reduce liver/lung accumulation due to phagocytosis. Compared to other chemical
polymers, the degradation of RNA can be timely controlled
by adjusting the percent and location of chemically modified
stable nucleotides [G13,G56-58]. Furthermore, our RNAbased Dendrimer-Gd(III)-chelate complex will retain the
reported favorable attributes of the pRNA-3WJ nanoparticles[G9-12], such as thermodynamic stability, desirable
pharmacokinetic profiles including free of normal organ
accumulation and strong cancer targeting, non-toxic nature,
and well-defined structure (monodisperse), while providing
additional high relaxivity properties of MRI contrast agents.
3.1 Construction of RNA Dendrimers Using pRNA-3WJ
Motif Harboring Gadolinium Contrast Agents, Radionuclides and Targeting Ligands
We previously applied a RNA nanotechnology based
bottom-up approach to construct large macromolecular
assemblies of RNA nanoparticles by branch extension of
pRNA-3WJ motif (FIG. 26)[Gll]. More recently, we solved
the crystal structure of the pRNA-3WJ scaffold 14 , which will
facilitate the design of RNA Dendrimers. The 3 WJ motif is
a highly programmable building block and can be used to
generate square shaped architectures (consisting of 3WJ
motifs at each comer) to serve as GO core. The square shape
will eliminate any steric hindrances that may arise in the
course of building higher-ordered structures. A step-wise
iterative assembly approach will then be applied via intramolecular interactions between pRNA-3WJ motifs to construct highly branched Generation-3 (G3) RNA Dendrimers
with precise control of size (-60 nm), shape (3D globular)
and stoichiometry (FIG. 26). From Section 1.1-1.2 of
Example 2 we will have constructed pRNA-3WJ harboring
NIR fluorophores, radionuclides, galodinium contrast agents
and folate targeting ligand. These functionalized pRNA3WJ units will be placed with control at any desired location
within the G3 construct to generate multifunctional G3 RNA
Dendrimers harboring gadolinium for MRI, radionuclides
for PET/SPECT imaging and folate, as a targeting ligand
(FIG. 26).
Our approach does not require any linkers, such as PEG
which has been used in higher-ordered Dendrimers to
increase Gd-payload, but with modest increase in relaxivity
(due to large amount of internal motion caused by PEG
linkers within Dendrimers)[G124]. In addition, our construct can be labeled with Gd-chelates on the outer surface
as well as inner core (which is readily accessible to water),
thereby ensuring higher Gd payloads without any crosslinking, such as those recently used to generate Dendrimer
porous nanoclusters[G124]. This in tum will reduce the dose
(lower than 0.2 mmol/kg that is clinically used for Magnevist™) employed for in vivo imaging and associated metal
toxicities. Finally, RNA Dendrimer constructs allow integration of targeting and imaging modules leading to the new
design of targeted contrast agents.
We will conjugate Gd(DOTA) to our RNA Dendrimers
(see Section 1.1.3 of Example 2 for conjugation), which is
known to be a better contrast agent in terms of chemical
stability (dissociation of the metal ion was exceedingly slow
even at low pH (2-4), on the order of days) and thus
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Example 4
Design pRNA-3WJ Dendrimers to Carry MRI Contrast
Agent and Radionuclides for Imaging in Colon Cancer
Mouse Models
This study focuses on construction of RNA Dendrimers
harboring targeting ligands, contrast agents for MRI, and
radioisotopes for PET/SPECT imaging and evaluate their
functionalities non-invasively in colon cancer mouse models.
MRI is a powerful imaging modality owing to its noninvasive nature, superb spatial resolution at the sub-millimeter range, and excellent potential for longitudinal studies109·122. Contrast agents have been employed to enhance
the sensitivity of the MRI scan. Clinically used FDAapproved low molecular weight contrast agents, such as
Gd(DTPA) (Magnevist®) or Gd(DOTA) (Dotarem®) suffer
from non-specificity; relative low signal enhancing effects;
rapid extravasation from the blood vessels; and fast elimination from the circulatory system. Therefore they often
require repeated administrations and high dosages, which in
turn induces false-positive contrast enhancements and Gdmediated toxicity (Nephrogenic Systemic Fibrosis)[G123].
In recent years, extensively branched 3D structures called
dendrimers have become an attractive platform for building
multifunctional macromolecular nanomaterials as diagnostic and therapeutic agents[G124-131]. MRI contrast agents
composed of multiple Gd(III) chelates assembled on a
dendrimer platform are much more efficient and effective in
modulating the longitudinal relaxation rate and time of water
protons, as compared to a single chelate unit analogue
[G109]. This was demonstrated with Gd(III) chelates to high
molecular weight carrier poly(amidoamine) (PAMAM) and
poly(propyleneimine) (PPI) dendrimers [G125,G127,G129,
G131-133] that prolonged intravascular retention and circu-
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potentially less toxic as compared to Gd(DTPA)[G136]. The
assembly of RNA Dendrimers will be verified by gel assays
and AFM (see Section 1.4 of Example 2). Transmission
Electron Microscopy (TEM) will then be used to confirm the
labeling of RNA Dendrimers with Gd. Since Gd ions are
electron dense, RNA-Gd Dendrimers can be directly imaged
on a carbon-coated copper grid without any additional
staining reagents.
3.2 In Vitro Characterization of RNA Dendrimers
3.2.1. Molar relaxivity measurements: Relaxivity
expresses the ability of a paramagnetic material to perform
as a MRI contrast agent. The water proton relaxation
enhancement by the Gd compound is dependent on the
concentration. It is quantitatively described by the equation
(1/T 1 )=(1/T 1 )+rl [Gd], where T 1 is the relaxation time of the
water proton: T 10 is the water proton relaxation time of pure
water, [Gd] is the concentration of the gadolinium compound, and rt is defined as the compound's relaxivity. The
relaxivity of a gadolinium compound can be quantitatively
described by the Solomon-Bloembergen-Morgan theory 137 .
The simplified model is represented by the equation rl =qP ml
(Tlm+-cm), where Pm is the concentration of water proton,
which is constant, q is the hydration number (the number of
water molecules bound to each Gd cation), and -cm is the
lifetime of the bound water molecule. Finally, Tim is a fitted
parameter (the bound water proton relaxation time), and is
decided by factors such as the strength of the magnetic field
and the size of the Gd compound. The Solomon-Bloembergen-Morgan theory precisely predicts the performance of the
Gd-based MRI contrast agents and aids the design of contrast agents with high relaxivity and 'smart' characteristics.
The relaxivity and relaxation rate constants of the RNA-Gd
Dendrimers will be compared to commercial contrast agent
Dotarem® at different magnetic field strengths and solution
conditions.
3.2.2. Assay Cell Binding and Uptake:
To confirm the folate receptor targeting capabilities of the
multifunctional RNA Dendrimers, HT29 colon cancer cells
will be incubated with RNA Dendrimer-Gd-FA-Alexa 647
constructs, with appropriate controls and subsequently analyzed by flow cytometry and confocal fluorescence microscopy (FIG. 15-16), as described in Example 3 at Section 2.1.
Cell proliferation (MTT) and apoptosis (TUNEL) assays
will also be performed to assay for specific cytotoxic effects.
To further investigate the MRI contrast capabilities, HT29
cells will be incubated with RNA Dendrimer-Gd-FA-Alexa 647 constructs and assessed by acquiring Tl-weighted
magnetic resonance images of HT29 cells that pelleted in
PCR tubes. HT29 cells in presence of Gd will exhibit a
significant enhancement in MR signal intensity compared
with control cells.
3.3 Characterization of RNA Dendrimers in Colon Cancer
Mouse Models
An advanced 3T Siemens Magnetom Trio scanner with
high performance gradients, echo-planar whole body imaging and hydrogen spectroscopic capabilities for both human
and animal studies. For dedicated animal studies, a modern
Brnker/Siemens 7T MR scanner will be used [G138,G139]
(FIG. 27) to evaluate our RNA Dendrimers.
We will generate subcutaneous, orthotopic and metastatic
colon cancer mouse models (see Section 2.2, described in
Example 3) to evaluate the multifunctional RNA DendrimerGd-Folate-radiolabel constructs, with appropriate controls.
Axial MR images of mice harboring tumors will be acquired
pre-contrast and at various time-points after intravenous
injection of RNA Dendrimers. In the pre-contrast images,
there will be little intrinsic contrast between the tumors and

surrounding muscle. Over time, specific signal enhancement
will be observed from the tumors compared to surrounding
tissues. Blood clearance rates will be determined from
intensity measurements of the jugular vein. Alternatively,
blood samples will be collected at various time points and
analyzed for Gd content. Detailed biodistribution and pharmacokinetic properties will be evaluated, following our
publication[G12] and as described in Example 3 at Section
2.2.4.
Due to the multimodal nature of the RNA Dendrimers, the
targeting of tumors and metastatic cells can be further
verified by fluorescence (using Alexa 647 ) and SPECT/PET
(using 177 Lu, 111 In or 64 Cu) imaging. There is a critical need
in medical imaging to co-register functional PET images
with MRI that offers detailed anatomical structures. PET
offers highest tumor detection sensitivity because of the use
of radiotracers. However, tumor sites with high radioactivity
cannot be accurately located in the abdomen or near the
boundary of a moving organ owing to a lack of anatomical
structure in PET images. MRI offers excellent soft-tissue
contrast and thus facilitates tumor localization in co-registered MRI and PET images.
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This study relates to programmable self-assembly of
branched, 3D globular, monodisperse and nanoscale sized
dendrimers using RNA as building blocks. The central core
and repeating units of the RNA dendrimer are derivatives of
the ultrastable three-way junction (3WJ) motif from the
bacteriophage phi29 motor pRNA. RNA dendrimers were
constructed by step-wise self-assembly of modular 3WJ
building blocks initiating with a single 3WJ core (Generation-0) with overhanging sticky-end and proceeding in a
radial manner in layers up to Generation-4. The final constructs were generated under control without any structural
defects in high yield and purity, as demonstrated by gel
electrophoresis and AFM imaging. Upon incorporation of
folate on the peripheral branches of the RNA dendrimers, the
resulting constructs showed high binding and internalization
into cancer cells. RNA dendrimers are envisioned to have a
major impact in targeting, disease therapy, molecular diagnostics and bioelectronics in the near future.
Methods
RNA Synthesis and Purification:
RNA oligonucleotides were prepared by chemical synthesis using a oligo synthesizer, custom ordered from Trilink
Biotechnologies, Inc. (San Diego, Calif., USA) or generated
by in vitro transcription of respective PCR amplified dsDNA
containing the T7 promoter46 . RNA strands were purified by
HPLC or by 8% Urea-PAGE. Single-stranded DNA templates and primers were purchased from Integrated DNA
Technologies (Coralville, Iowa, USA).
Construction of G-0 to G-4 Dendrimers:
Dendrimers structure G-0, G-1, G-2 and G-3 were constructed using one-pot self-assembly of component strands
(see sequences below). For G-0, the three component strands
(3WJ-a):(3WJ-b):(3WJ-c)=l:1:1 molar ratio; For G-1, the
five component strands (SquareA): (SquareB):(SquareC):
(SquareD):(SquareE)=l:1:1:1:1 molar ratio. For G-2, the
seven component strands (b-SquareA):(b-SquareB):(bSquareC):(b-SquareD):(SquareE): (3WJ-a):(3WJ-c )=1: 1: 1:
1:1:4:4 molar ratio. For G-3, the nine component strands
(b-SquareA):(b-SquareB):(b-SquareC):(b-SquareD):(SquareE):(3WJ-c-b_rev):(3WJ-a-b_rev):(3WJ-a_rev):
(3WJc_rev)=l: 1: 1:1:1 :4:4:8:8 molar ratio. The required dendrimer RNA strands were mixed together in stoichiometric
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ratio in TMS buffer (25 mM Tris, 50 mM NaCl, 5 mM
MgC1 2 ) and the mixture was heated to 95° C. for 5 min and
(11) SquareD,
then slowly cooled to 4° C. at a rate of 2° C./min on an
Eppendorfthermocycler. The assembly efficiency was veriGGG ACC AGC CAA
fied using 8% native PAGE or 2% agarose gel.
5
UGU UGA CGG CGG
For the construction of G-4 dendrimer, a two-step
approach was used. First, the dendrimer nanostructure G-2
( 12) SquareE,
with sticky ends was constructed by mixing together
required RNA strands with appropriate stoichiometry in
GGA CAC UUG UCA
TMS buffer. The mixture was heated to 95° C. for 5 min and 10
UGU AUG CUC UAU
then slowly cooled as described above for the construction
ofG-1, G-2 and G-3 dendrimer generations. The free strands
UUG UCA UGU GUA
were removed by passing the mixture through Amicon
(13) b-SquareA,
Ultracentrifugal spin filters with 100 KDa cut off following
manufacturer protocol and washed twice with TMS buffer. 15
GGC CCA CAU ACU
The pure G-2 with sticky ends was collected from colunm.
In second step, the G-2 with sticky ends was mixed in
CGU CAA UCA UGG
stoichiometric ratio with other RNA strands needed to form
ACU CCC UUG CUC
G-4. The final molar ratio of the 11 G-4 component strands
are
(b-SquareA):(b-SquareB):(b-SquareC):(b-SquareD): 20 (14) b-SquareB,
(SquareE):(3WJ-c-b_rev):(3WJ-a-b_rev):(3WJ-b-a_rev):
GGC CCA CAU ACU
(3WJ-b-c_rev):(3WJ-a):(3WJ-c )=1: 1: 1: 1: 1:4:4:8:8: 16: 16.
The mixture was incubated at room temperature for 1 hour.
GUG CAA UCA UGG
Then, an agarose gel was run to check assembly efficiency.
G-4 was constructed with a maximum final concentration of 25 GAA CCC UAU GUG
1 µM in TMS buffer.
(15) b-SquareC,
The sequences of all the strands of the RNA dendrimers
are as follows (Sequence 5'----;.3'):
GGC CCA CAU ACU

-continued
(SEQ ID NO, 11)
UCA UGG CAA UAU ACA CGC AUA CUU

( SEQ ID NO, 12)
UGU GUA UGC GUG UAU AUU GUC AUG
CGU UGU CAU GUG UAU GCG AUG CGC
UGG C

( SEQ ID NO, 13)
UUG UUG AUC CAU GGU GCG UAG GGU
CAA GUG UCC GCC AUA CUU UGU UGC
AUC A

( SEQ ID NO, 14)
UUG UUG AUC CUG AUG AGC AAG GGA
CAA GCG UAU CGC AUA CUU UGU UGA
ACU U

(SEQ ID NO, 15)
UUG UUG AUC CAA GUC ACA UAG GGU

30 UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU UGU UGG
(1) 3WJ-a,
AGU CCC UUA GAG UAG A

(SEQ ID NO, 1)
UUG CCA UGU GUA UGU GGG

(16) b-SquareD,
(2) 3WJ-b,
(SEQ ID NO, 2)
CCC ACA UAC UUU GUU GAU CC

(SEQ ID NO, 16)
35 GGC CCA CAU ACU UUG UUG AUC CUC UAC UCU AAG GGA
CUC CAA UCA UGG CAA UAU ACA CGC AUA CUU UGU UGA

(3) 3WJ-c,
CGA CCC UAC GCA CCA U

(SEQ ID NO, 3)
GGA UCA AUC AUG GCA A
40

(4) 3WJ-a rev,
(SEQ ID NO, 4)
GGG UGU AUG UGU ACC GUU

(17) 3WJ-a-b rev,
( SEQ ID NO, 1 7)
UUG CCA UGU GUA UGU GGG CCU AGU UGU UUC AUA CAC

cc

(5) 3WJ-b rev,
(SEQ ID NO, 5)
CCU AGU UGU UUC AUA CAC CC

(18) 3WJ-c-b rev,
45

(SEQ ID NO, 18)
GGA UCA AUC AUG GCA A CCU AGU UGU UUC AUA CAC CC

(6) 3WJ-c rev,
(19) 3WJ-b-a rev,

(SEQ ID NO, 6)

(SEQ ID NO, 19)
CCC ACA UAC UUU GUU GAU CC GGG UGU AUG UGU ACC

AAC GGU ACU AAC UAG G
(7) 3WJ-c-folate,

50

(SEQ ID NO, 7)

GUU

GGA UCA AUC AUG GCA A - folate
(20) 3WJ-b-c rev,
(SEQ ID NO, 20)
CCC ACA UAC UUU GUU GAU CC AAC GGU ACU AAC UAG G

(8) SquareA,
(SEQ ID NO, 8)
GGG AGC CGU CAA UCA UGG CAA GUG UCC GCC AUA CUU

55

UGU UGC ACG CAC
(9) SquareB,
(SEQ ID NO, 9)
GGG AGC GUG CAA UCA UGG CAA GCG CAU CGC AUA CUU

60

UGU UGC GAC CUA
(10) SquareC,
(SEQ ID NO, 10)
GGG AGG UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU
65

UGU UGG CUG GAG

Gel Analysis:
RNA dendrimers were analyzed using 2% agarose gel and
6-8% PAGE. The gels were prepared and ran in TMS buffer
at 90 V for 1 hr. The gels were stained with ethidium
bromide and scamied using Typhoon FLA 7000 (GE Healthcare, Cincinnati, Ohio, USA).
AFM Imaging:
Dendrimer structures were imaged using APS modified
mica surfaces with a Multi-Mode AFM Nano-Scope IV
system (Veeco/Digital Instruments, Town of Oyster Bay,
N.Y., USA), operating in tapping mode, as described previously47.
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Serum Stability Assay:
The chemical stability ofRNAdendrimers was studied by
incubating the dendrimers with 50% Fetal Bovine Serum
(FBS) at 37° C. at final concentration of 1 µM. 10 µL of
samples were collected at each time point (0, 0.16 hr, 1 hr,
3 hr, 6 hr, 18 hr, and 24 hr) and were subjected to a 2%
agarose gel assay with TBM running buffer. The gel was run
at 120 V for 120 minutes, imaged by Typhoon FLA 7000
(GE Healthcare, Cincinnati, Ohio, USA), and gel bands
quantified by Image J.
Flow Cytometry Analysis:
Folate receptor (+) KB Cells were cultured in T75 flask
and harvested at a density of lxl0 6 cells/ml with 0.25%
trypsin. Cells were washed with Opti-MEM medium once
and then incubated with different concentration of Cy5
labeled 2'-F RNAdendrimers in Opti-MEMmedium for 1 hr
at 37° C., protected from light. Cells were then washed three
times and suspended in PBS (137 mM NaCl, 2.7 mM KC!,
100 mM Na2 HPO 4 , 2 mM KH 2 PO4 , pH 7.4) for analysis.
Confocal Imaging:
KB cells were grown in cover glass (Thermo Fisher
Scientific, Waltham, Mass., USA) in 24 well bottom culture
dishes in its complete medium overnight. Cells were seeded
at a density of 2xl 0 5 cells/ml in a volume of 500 µI. On the
day of testing, cells were washed with Opti-MEM medium
twice, and RNA dendrimer (with whole chain Cy5 labeled
SquareE-strand) were suspended in 200 µI of Opti-MEM
medium and incubated with cells at 37° C. for 1 hr. Cells
were washed with PBS twice, fixed with 4% paraformaldehyde solution (Microscopy Sciences, Hatfield, Pa., USA) in
PBS at room temperature for 20 min, then washed with PBS
and permeabilized with 0.05% Triton-X 100 in PBS at room
temperature for 3 min. The cells were then stained with
Alexa488 phallodin (Thermo Fisher Scientific, Waltham,
Mass., USA) at room temperature for 20 min, the wells
washed with PBS and air dried. The cells were stained with
gold antifade (Thermo Fisher Scientific, Waltham, Mass.,
USA) for DAPI staining for confocal microscopy imaging
with Zeiss LSM 510 laser scanning system.
Results
Design and Assembly of Parts and Intermediates for RNA
Dendrimers
We developed three modules as building blocks for construction of RNA dendrimers. Module-I is the 3WJ motif
composed of three individual strands (3WJ-a, 3WJ-b and
3WJ-c) with three terminal ends (FIG. 28A). In order to
build higher order structures, we need to interconnect the
3WJ motifs in a radial manner, and this requires using two
different 3WJs with near identical folding properties to
avoid cross-talk between layers. Otherwise, misfolding and
aggregation can occur. We generated a reverse pRNA-3WJ,
denoted pRNA-3WJ-rev, which is a mirror image of the
pRNA-3WJ with the 5'- and 3'-ends switched (FIG. 28B).
The pRNA-3WJ-rev has identical properties as the conventional pRNA-3WJ with regards to thermodynamic stability,
as well as assembly in native and 8 M denaturing PAGE.
Module-2 consists of three sets of pRNA-3WJ building
blocks, each harboring one of the component strands of the
pRNA-3WJ-rev serving as sticky ends (3WJ-a_rev, 3WJb_rev and 3WJ-c_rev). The use of3WJ core strands as sticky
ends ensures near spontaneous 3WJ assembly with minimal
non-specific hybridization, which can otherwise lead to
misfolding, and also eliminates the need for additional
linking sequences between 3WJs.
Upon mixing the three building blocks in stoichiometric
ratio, the pRNA-3WJ-rev assembles from the three sticky-

ends thereby generating module-2 with high efficiency (FIG.
29). Module-2 is composed of 5 component strands and has
6 terminal ends.
Similarly, module-3 was constructed from iterative stepwise assembly on top of module-2 complexes by branch
extension using one of the 3WJ component strands as sticky
ends. The final complex is composed of 7 strands and 12
terminal ends with alternating pRNA-3WJ core and pRNA3WJ-rev cores (FIG. 29).
All three modules can be assembled either in one step or
step-wise by simply mixing the strands at room temperature
in TMS buffer (40 mM Tris, 10 mM MgCl 2 , 100 mM NaCl)
or by annealing (heating to 95° C. and cooling to room
temperature over the course of 1 hour). The use of these
modules will enable construction of RNA dendrimers with
desired functional moieties, such as RNAi reagents siRNA,
miRNA, anti-miRNA; chemotherapeutic drug; receptor targeting RNA aptamer or chemical ligand; riboswitch;
ribozyme; endosome disrupting agents; and imaging fluorophores or radiolabels (FIG. 30).
Design and Assembly of RNA Dendrimers G-0 to G-4
RNA dendrimers have similar architectures as small molecule based dendrimers consisting of an initiating core,
interior layer of repeating units, and terminal units at the
peripheral ends of the outermost generation. In the traditional sense, we adopted a 'divergent growth' method,
whereby the dendrimer initiates from a core site and grows
in a radial manner layer by layer. We used the pRNA-3WJ
as G-0 initiating core (FIG. 29A, 32A-B) and then constructed a planar square nanoparticle to serve as G-1 (FIG.
31A, 32A-B). The pRNA-3WJ scaffold is highly tunable and
the internal angle can be stretched from native 60° to 90° in
the square configuration, as demonstrated previously30 . The
pRNA-3WJ cores at each vertex is linked by double
stranded RNA sequences, with the entire square construct
(G-1) composed of 5 strands and 4 terminal ends (MW -83
KDa) (FIG. 31A). The square pattern ensures equal spacing
between the protruding corner branches and minimizes
steric hindrances for addition of building blocks. We then
adopted a similar strategy as aforementioned using one of
the 3WJ component strands as sticky ends to sequentially
construct G-2 (7 unique strands; 8 terminal ends; MW -187
kDa) (FIG. 318, 32A-B), G-3 (9 unique strands; 16 terminal
ends; MW -328 kDa) (FIG. 31C, 32A-B) and finally G-4 (11
unique strands; 32 terminal ends; MW -610 kDa) (FIG.
31D, 32A-B) (Table 4). G-0 through G-3 dendrimers can be
assembled with high yield by mixing the component strands
in equimolar ratio followed by annealing, except for G-4,
which requires an additional incubation step with module-2
(FIG. 29, 31D). Our design does not require any enzymatic
ligation step and simply relies on self-assembly of individual
blocks for the construction of higher order dendrimers. All
the sequences for dendrimer generations were optimized to
avoid any nonspecific interactions using the Mfold algorithm [D48].
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TABLE 4
Characteristics of RNA dendrimers
60
RNA
Dendrimer
G-0
65

G-1

Predicted
Size
(nm)
6

12

Molecular
Weight
(kDa)

# of
strands

# of
nucleotides

Terminal
units

17784

3 unique

54

3

82843

3 total
5 unique
5 total

440

4
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TABLE 4-continued

To further confirm the results, all constructed dendrimer
generations from G-0 to G-4 were examined by AFM
imaging, which strongly support the formation of all dendrimers with branched conformations (FIG. 32A). For G-4
dendrimers, the bifurcation in the arms of outer layer can be
easily observed and the central square is visible in most of
the structures from G-1 to G-4. The dendrimer structures are
indeed three dimensional as designed in silica utilizing the
crystal structure of the planer 3WJ structural motif]D44].
Swiss PDB Viewer (www.spdbv.vital-it.ch) and Pymol
(https://www.pymol.org/) were used to align 3WJ building
blocks into three dimensional structure models (FIG. 32A),
based on the available crystal structure of pRNA-3WJ (PDB
ID: 4KZ2)[D44]. The three dimensional nature of dendrimer
make the structures to appear in different orientations on the
surface for AFM imaging thus bringing dendrimer arms
appear close or farther away from each other in different
images. RNA dendrimers are highly negatively charged and
do not aggregate in solution. This anionic nature and aggregation-free physical property will minimize non-specific cell
entry, and entrapment by lung and spleen macrophages and
liver Kupffer cells[D53].
Characterization of RNA Dendrimers for Cell Receptor
Targeting
To study the potential applications of RNA dendrimers in
targeting specific cells, 2'-F modified RNA dendrimers were
assembled with targeting ligands at peripheral ends.
Increased expression of folate receptors are frequently
observed in cancer cells of epithelial origin54 . Herein, we
used folate as a targeting ligand. Within G-4, the core
SquareE strand of G-1 was fluorescently tagged with Cy5
for detection. One of the terminal end sequences (3WJ-c)
was labeled with folate at 3'-end (custom ordered from
Trilink) and then used to assemble G-4 dendrimers resulting
in 16 folates distributed evenly across the G-4 dendrimer
surface. Folate receptor positive KB cells were incubated
with G-4 dendrimers at different concentrations and the
incubation efficiencies were analyzed using flow cytometry
(FIG. 33A). G-4 dendrimers with folate displayed increase
in intracellular uptake with increasing RNA concentrations
from 1 nM to 3 nM to 6 nM, compared to G-4 dendrimers
without any folate. This is attributed to folate receptor
mediated endocytosis. Confocal fluorescence microscopy
(FIG. 33B) images further confirmed the internalization of
G-4 dendrimers with folates as indicated by strong overlap
of cytoplasma (green) and dendrimers (red). The results
demonstrate that RNA dendrimers would be useful to deliver
various payloads including radioligand, drug molecules, and
RNAi modules into the cells.
Discussion
We demonstrated that RNA can serve as a new generation
of building blocks to form homogenous supramolecular 3D
dendrimers with defined size and shape. Our step-wise self
assembly strategy utilizing a robust pRNA-3WJ motif is
highly efficient and can generate homogeneous dendrimers
under control with high yield and purity. Introduction of2'-F
RNA makes the dendrimers serum resistant and decoration
of the dendrimers with targeting ligands results in high
intracellular delivery to specific target cells.
Compared to small molecule based chemical polymers,
RNA dendrimers can be made large enough (>10 nm) to
avoid rapid renal excretion, yet small enough ( 65 nm for G-4
dendrimers) to enter cells via receptor-mediated endocytosis. The degradation of RNA can be timely controlled by
adjusting the percent and location of chemically modified
2'-F nucleotides. Moreover, individual nucleotides within
the RNA dendrimer can be labeled during chemical synthe-

Characteristics of RNA dendrimers

Dendrimer

Predicted
Size
(nm)

Molecular
Weight
(kDa)

G-2

37

186675

G-3

50

327675

G-4

65

609675

RNA

# of

strands
7 unique
13 total
9 unique
29 total
11 unique
61 total

# of
nucleotides

Terminal
units

5

576
1008

16

1872

32

10

Characterization of RNA dendrimers for thermodynamic
stability and serum stability
The thermodynamic stability of individual building
blocks is of paramount importance to ensure that the RNA
dendrimers remain intact without dissociating in vivo. Both
the pRNA-3WJ and pRNA-3WJ-rev scaffold assemble with
high efficiency, as shown in native PAGE (FIG. 28A-B; top
gel). Both 3WJs remain stable in presence of strongly
denaturing 8 M urea, thereby demonstrating the robust
attributes (FIG. 28A-B; bottom gel). Melting experiments
indicated that the three component strands have a much
higher affinity to interact with one another than any of the
one or two component strands. The slope of the melting
curve is very steep indicating cooperative assembly of the
three strands with very low free energy (li.G 0 38 - c. of -28
kcal/mo!), as calculated previously 37 . The Tm values are near
identical for pRNA-3WJ and pRNA-3WJ-rev scaffolds with
59±0.5° C. and 58.5±0.5° C., respectively (FIG. 28A-B). Tm
analysis of RNA dendrimers is challenging involving multiple strands and multi-step folding intermediates.
For successful clinical application of RNA dendrimers, a
major hurdle is their stability in biological media, such as
serum. Unmodified RNAs are intrinsically sensitive to degradation because of presence of nucleases in serum or in
cells with a half-life varying from a few minutes to several
hours[D40,D49,D50]. Chemical modifications, such as
2'-Fluoro (2'-F) modification on the ribose sugar of the
RNA, have been shown to be nuclease resistant [D22,D51,
D52] and also enhance the thermodynamic stability of RNA
nanoparticles [D37]. Within the dendrimer RNA sequences,
the U and C nucleotides were replaced by 2'-F modified U
and C nucleotides during solid state synthesis or in vitro
transcription. The 2'-F modified G-4 RNA dendrimers were
assembled and showed similar assembly efficiency as
unmodified G-4 RNA dendrimers in native gel assays. To
test the serum stability, 2'-F modified G-4 dendrimers were
incubated with 10% Fetal Bovine Serum (FBS) at 37° C. At
specific time points, aliquots were extracted and snap frozen.
Gel assays demonstrated that the 2'-F G-4 RNA dendrimers
are resistant to nuclease degradation for more than 24 hours
(FIG. 32C), while unmodified constructs are degraded
within 10-15 minutes.
Characterization of RNA Dendrimer Assembly by Atomic
Force Microscopy (AFM) and Gel Electrophoresis
The assembly of dendrimers was tested by native gel
electrophoresis (FIG. 32B). G-0, G-1, G-2, G-3 and G-4
dendrimers all display a single band in the gels without any
smears indicating high efficiency of the adopted assembly
strategy. No significant change in assembly efficiency was
observed by going from lower to higher generations. The
free RNA strands were removed after dendrimer assembly
using centrifugal membrane filter colunms. The slow migration of the gel band from G-0 to G-4 clearly indicates the
increasing size of the constructs, as expected.
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sis prior to dendrimer self-assembly, thus ensuring full
utilization of void-spaces, which is an arduous challenge for
small molecule based dendrimers. Compared to DNA counterparts, in addition to enhanced chemical stability after 2'-F
modifications, RNA dendrimers are thermodynamically
more stable[D15-16,D22,D37,D55-56] and will therefore
not dissociate at ultra-low concentrations in vivo, and therapeutic RNA interference modules, such as siRNA and
miRNA can be seamlessly integrated into the sequence
design.
The ease of chemical synthesis of RNA strands, the
simplicity of self-assembly without synthetic reactions, the
ease of functionalization of modular units prior to assembly,
and the multivalent nature of RNA dendrimers will help in
high loading of desired functional modules, such as drugs,
targeting, therapeutic, and imaging agents for myriad of
applications in bioelectronics, biomimetic membranes,
imaging, diagnostics and therapeutics.
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It will be understood that various details of the presently
disclosed subject matter can be changed without
departing from the scope of the subject matter disclosed
herein. Furthermore, the foregoing description is for the
purpose of illustration only, and not for the purpose of
limitation.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 37
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 18
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 1
uugccaugug uauguggg

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 2
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 2
cccacauacu uuguugaucc

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 3
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
ggaucaauca uggcaa

<210>
<211>
<212>
<213>
<220>
<223>

16

SEQ ID NO 4
LENGTH, 18
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 4
ggguguaugu guaccguu

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 5
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
ccuaguuguu ucauacaccc

<210> SEQ ID NO 6
<211> LENGTH, 16
<212> TYPE, RNA

20
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74

73
-continued
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<400> SEQUENCE, 6
aacgguacua acuagg

16

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<220> FEATURE,
<223> OTHER INFORMATION, 3'-folate
<400> SEQUENCE, 7
ggaucaauca uggcaa

<210>
<211>
<212>
<213>
<220>
<223>

16

SEQ ID NO 8
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 8
gggagccguc aaucauggca aguguccgcc auacuuuguu gcacgcac

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 9
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 9
gggagcgugc aaucauggca agcgcaucgc auacuuuguu gcgaccua

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 10
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 10
gggaggucgc aaucauggca acgauagagc auacuuuguu ggcuggag

<210>
<211>
<212>
<213>
<220>
<223>

48

SEQ ID NO 11
LENGTH, 48
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 11
gggaccagcc aaucauggca auauacacgc auacuuuguu gacggcgg

<210> SEQ ID NO 12
<211> LENGTH, 88

48
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75
-continued
<212>
<213>
<220>
<223>

TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 12
ggacacuugu cauguguaug cguguauauu gucaugugua ugcucuaucg uugucaugug

60

uaugcgaugc gcuugucaug uguauggc

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 13
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 13
ggcccacaua cuuuguugau ccauggugcg uagggucguc aaucauggca aguguccgcc

60

auacuuuguu gcacucccuu gcucauca

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 14
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 14
ggcccacaua cuuuguugau ccugaugagc aagggagugc aaucauggca agcguaucgc

60

auacuuuguu gagaacccua ugugacuu

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 15
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 15
ggcccacaua cuuuguugau ccaagucaca uaggguucgc aaucauggca acgauagagc

60

auacuuuguu ggagucccuu agaguaga

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 16
LENGTH, 88
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 16
ggcccacaua cuuuguugau ccucuacucu aagggacucc aaucauggca auauacacgc

60

auacuuuguu gacgacccua cgcaccau

88

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 17
LENGTH, 38
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
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78
-continued

oligonucleotide

<400> SEQUENCE, 17
uugccaugug uaugugggcc uaguuguuuc auacaccc

<210>
<211>
<212>
<213>
<220>
<223>

38

SEQ ID NO 18
LENGTH, 36
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 18
ggaucaauca uggcaaccua guuguuucau acaccc

<210>
<211>
<212>
<213>
<220>
<223>

36

SEQ ID NO 19
LENGTH, 38
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 19
cccacauacu uuguugaucc ggguguaugu guaccguu

<210>
<211>
<212>
<213>
<220>
<223>

38

SEQ ID NO 20
LENGTH, 36
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 20
cccacauacu uuguugaucc aacgguacua acuagg

36

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 21
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide
<400> SEQUENCE, 21
ggaccaccgc aucucuacat t

21

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 22
LENGTH, 21
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
<220> FEATURE,
<223> OTHER INFORMATION, Description of Combined DNA/RNA Molecule,
Synthetic oligonucleotide
<400> SEQUENCE, 22
ttccuggugg cguagagaug u

<210> SEQ ID NO 23

21
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79
-continued
<211>
<212>
<213>
<220>
<223>

LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 23
aagcugucac agaggggcua c

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 24
LENGTH, 21
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 24
guagccccuc ugugacagcu u

<210>
<211>
<212>
<213>
<220>
<223>

21

SEQ ID NO 25
LENGTH, 25
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 25
ccaugugcua uacagucauu acuuu

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 26
LENGTH, 25
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 26
aaaguaauga cuguauagca caugg

<210>
<211>
<212>
<213>
<220>
<223>

25

SEQ ID NO 27
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 27
uuggacaaug gacugguuga

<210>
<211>
<212>
<213>
<220>
<223>

20

SEQ ID NO 28
LENGTH, 20
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 28
ucaaccaguc cauuguccaa

<210> SEQ ID NO 29
<211> LENGTH, 19

20
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-continued
<212>
<213>
<220>
<223>

TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 29
19

ccacauaaag ggcccacua

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 30
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 30
uagugggccc uuuaugugg

<210>
<211>
<212>
<213>
<220>
<223>

19

SEQ ID NO 31
LENGTH, 9
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 31
Gly Ser Gly Lys Cys Cys Tyr Ser Leu
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 32
LENGTH, 6
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
peptide

<400> SEQUENCE, 32
Lys Cys Cys Tyr Ser Leu
1

<210>
<211>
<212>
<213>
<220>
<223>

5

SEQ ID NO 33
LENGTH, 117
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polynucleotide

<400> SEQUENCE, 33
gcaaugguac gguacuucca uugucaugug uauguugggg auuaggaccu gauugaguuc
agcccacaua cuuuguugau ugcgcgucaa ucauggcaaa agugcacgcu acuuugc

<210>
<211>
<212>
<213>
<220>
<223>

60

117

SEQ ID NO 34
LENGTH, 16
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 34
ggaucaacca uggcaa

16
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<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 35
LENGTH, 34
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide
FEATURE,
NAME/KEY, modified_base
LOCATION, (1) .. (6)
OTHER INFORMATION, a, c, t, g, unknown or other
FEATURE,
NAME/KEY, modified_base
LOCATION, (29) .. (34)
OTHER INFORMATION, a, c, t, g, unknown or other

<400> SEQUENCE, 35
34

nnnnnntcaa catcagtctg ataagctann nnnn

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 36
LENGTH, 18
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 36
uugucaugug uauguugg

<210>
<211>
<212>
<213>
<220>
<223>

18

SEQ ID NO 37
LENGTH, 19
TYPE, RNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 37
ggguuguaug uguacuguu

What is claimed is:
1. A RNA dendrimer molecule, the molecule comprising
(a) a central core multi-branched RNA junction motif,
wherein the central core motif comprises a plurality of
branches, wherein a branch comprises at least one RNA
oligonucleotide, and wherein the central core motif comprises at least one RNA oligonucleotide having at least 90%
identity to SEQ ID NO: 12 (SquareE); and (b) an outer
surface multi-branched RNA junction motif comprising at
least one repeating multi-branched RNA junction motif unit,
wherein the repeating unit comprises a plurality of branches,
and wherein a branch comprises at least one RNA oligonucleotide.
2. The RNA dendrimer molecule of claim 1, further
comprising at least one imaging module, at least one targeting module, at least one therapeutic module, or a combination thereof.
3. The RNA dendrimer molecule of claim 1, wherein the
plurality of branches comprising the central core multibranched RNA junction motif comprises a three-branched
RNA junction motif, or four-branched RNA junction motif,
a six-branched RNA junction motif, or an eight-branched
RNA junction motif.
4. The RNA dendrimer molecule of claim 1, wherein the
plurality of branches comprising the repeating multi-

19

45

50

55

60

65

branched RNA junction motif unit comprises a threebranched RNA junction motif, or a four-branched RNA
junction motif, a six-branched RNA junction motif, and an
eight-branched RNA junction motif.
5. The RNA dendrimer molecule of claim 3 or 4, wherein
the three-branched RNA junction motif comprises an a3WJ
RNA module having at least 90% identity to nucleotide
sequence 5'-UUG CCA UGU GUA UGU GGG-3' (SEQ ID
NO: 1); a b3WJ RNA module having at least 90% identity
to nucleotide sequence 5'-CCC ACA UAC UUU GUU
GAUCC-3' (SEQ ID NO: 2); or a c3WJ RNA module having
at least 90% identity to nucleotide sequence 5'-GGA UCA
AUC AUG GCA A-3' (SEQ ID NO: 3), or a combination
thereof.
6. The RNA dendrimer molecule of claim 3 or 4, wherein
the central core multi-branched RNA junction motif is a
polygon shaped architecture comprising a three-branched
RNA junction motif at each comer.
7. The RNA dendrimer molecule of claim 1, wherein the
imaging module comprises a fluorescent dye, a radionuclide,
a contrast agent, a reporter imaging molecule, a reference
imaging molecule, or any combination thereof.
8. The RNA dendrimer molecule of claim 7, wherein the
reference imaging module comprises a reference dye and a
quencher.
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9. The RNA dendrimer molecule of claim 7, wherein the

-continued

contrast agent comprises at least one MRI contrast agent, at
least one gadolinium contrast agent, or both.
10. The RNA dendrimer molecule of claim 2, wherein the

targeting module comprises a cancer targeting module.

SquareA,
(SEQ ID NO, 8)
GGG AGC CGU CAA UCA UGG CAA GUG UCC GCC AUA CUU
5

UGU UGC ACG CAC

11. The RNA dendrimer molecule of claim 10, wherein
SquareB,

the cancer targeting module is a ligand that binds to at least
one cancer cell surface marker.
12. The RNA dendrimer molecule of claim 10, wherein
the targeting module comprises chemical ligand or RNA
aptamer.

(SEQ ID NO, 9)
GGG AGC GUG CAA UCA UGG CAA GCG CAU CGC AUA CUU
10

UGU UGC GAC CUA
SquareC,
(SEQ ID NO, 10)
GGG AGG UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU

13. The RNA dendrimer molecule of claim 11, wherein

the ligand comprises folate.
14. The RNA dendrimer molecule of claim 11, wherein

15

the cell surface markers comprises a folate receptor.

SquareD,

15. The RNA dendrimer molecule of claim 11, wherein

the ligand binds to an epithelial cell adhesion molecule
(EpCAM).

UGU UGG CUG GAG

(SEQ ID NO, 11)
GGG ACC AGC CAA UCA UGG CAA UAU ACA CGC AUA CUU
20 UGU UGA CGG CGG

16. The RNA dendrimer molecule of claim 11, wherein
SquareE,

the cell surface marker comprises an epithelial cell adhesion
molecule (EpCAM).
17. The RNA dendrimer molecule of claim 12, wherein
the aptamer is an EpCAM RNA aptamer.
18. The RNA dendrimer molecule of claim 2, wherein the
therapeutic module comprises a siRNA, a miRNA, an antimRNA, a ribozyme RNA, an antisense RNA, a chemotherapeutic drug, a cytotoxic drug, a riboswitch, or an endosome
disrupting agent.

(SEQ ID NO, 12)
GGA CAC UUG UCA UGU GUA UGC GUG UAU AUU GUC AUG
25 UGU AUG CUC UAU CGU UGU CAU GUG UAU GCG AUG CGC

UUG UCA UGU GUA UGG C
b-SquareA,
(SEQ ID NO, 13)
30 GGC CCA CAU ACU UUG UUG AUC CAU GGU GCG UAG GGU
CGU CAA UCA UGG CAA GUG

19. The RNA dendrimer molecule of claim 18, wherein

the cytotoxic drug comprises doxorubicin, paclitaxel, paclitaxel derivatives and analogues, cytochalasin D, rapamycin,
rapamycin derivatives and analogues, camptothecin, dexamethasone, and 5-fluorouracil, a quinazolinone derivative,
metallic silver, tranilast, everolimus and/or related compounds.
20. The RNA dendrimer molecule of claim 1, wherein the
RNA dendrimer molecule further comprises an oligonucleotide having at least 90% identity to nucleotide sequences of
at least one of

ucc

GCC AUA

cuu

UGU UGC

ACU CCC UUG CUC AUC A
35

b-SquareB,
(SEQ ID NO, 14)
GGC CCA CAU ACU UUG UUG AUC CUG AUG AGC AAG GGA
GUG CAA UCA UGG CAA GCG UAU CGC AUA CUU UGU UGA

40

GAA CCC UAU GUG ACU U
b-SquareC,
(SEQ ID NO, 15)
GGC CCA CAU ACU UUG UUG AUC CAA GUC ACA UAG GGU

45 UCG CAA UCA UGG CAA CGA UAG AGC AUA CUU UGU UGG

3WJ-a,
(SEQ ID NO, 1)
UUG CCA UGU GUA UGU GGG

AGU CCC UUA GAG UAG A
b-SquareD,

3WJ-b,
(SEQ ID NO, 2)
CCC ACA UAC UUU GUU GAU CC
3WJ-c,

(SEQ ID NO, 16)
AAG GGA

50 GGC CCA CAU ACU UUG UUG AUC CUC UAC

ucu

CUC CAA UCA UGG CAA UAU ACA CGC AUA

cuu

UGU UGA

(SEQ ID NO, 3)
GGA UCA AUC AUG GCA A

CGA CCC UAC GCA CCA U

3WJ-a rev:

(SEQ ID NO, 4)
GGG UGU AUG UGU ACC GUU
3WJ-b rev,
(SEQ ID NO, 5)
CCU AGU UGU UUC AUA CAC CC

55 3WJ-a-b rev:

(SEQ ID NO, 17)
UUG CCA UGU GUA UGU GGG CCU AGU UGU UUC AUA CAC

cc
60 3WJ-c-b rev:

3WJ-c rev:

(SEQ ID NO, 6)

(SEQ ID NO, 18)
GGA UCA AUC AUG GCA A CCU AGU UGU UUC AUA CAC CC

AAC GGU ACU AAC UAG G
3WJ-b-a rev,
3WJ-c-folate,
(SEQ ID NO, 7)
GGA UCA AUC AUG GCA A - folate

(SEQ ID NO, 19)
65 CCC ACA UAC UUU GUU GAU CC GGG UGU AUG UGU ACC GUU
or
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-continued
3WJ-b-c rev,
(SEQ ID NO,

20)

CCC ACA UAC UUU GUU GAU CC AAC GGU ACU AAC UAG G.

21. A composition comprising a therapeutically effective
amount of the RNA dendrimer molecule of claim 1 and a
pharmaceutically effective carrier.
22. The RNA dendrimer molecule of claim 1, wherein the
central core motif further comprises an RNA oligonucleotide
having at least 90% identity to at least one of SEQ ID NO:
8 (SquareA), SEQ ID NO: 9 (SquareB), SEQ ID NO: 10
(SquareC), SEQ ID NO: 11 (SquareD), SEQ ID NO: 13
(b-SquareA), SEQ ID NO: 14 (b-SquareB), SEQ ID NO: 15
(b-SquareC), or SEQ ID NO: 9 (b-SquareD).

* * * * *

10

15

